<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="24672"><DrugName>vorapaxar</DrugName><DrugNamesKey><Name id="43026351">Zontivity</Name><Name id="42923777">vorapaxar</Name><Name id="42924040">vorapaxar sulfate</Name></DrugNamesKey><DrugSynonyms><Name><Value>thrombin receptor antagonist, Schering-Plough</Value></Name><Name><Value>SCH-530348</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>TRA (atherothrombosis), Schering-Plough</Value></Name><Name><Value>vorapaxar</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>vorapaxar sulfate</Value><Types><Type>USAN</Type></Types></Name><Name><Value>MK-5348</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Zontivity</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>312617-89-3</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="24009">Schering-Plough Research Institute</CompanyOriginator><CompaniesPrimary><Company id="18077">Merck &amp; Co Inc</Company><Company id="1110015">Old API Wind-down Ltd</Company></CompaniesPrimary><CompaniesSecondary><Company id="19711">Schering-Plough Corp</Company><Company id="24009">Schering-Plough Research Institute</Company></CompaniesSecondary><CrossReferences><SourceEntity id="24672" type="Drug"><TargetEntity id="353335" type="siDrug">Vorapaxar</TargetEntity><TargetEntity id="641351" type="siDrug">Vorapaxar sulfate</TargetEntity></SourceEntity><SourceEntity id="18077" type="Company"><TargetEntity id="4295904886" type="organizationId">Merck &amp; Co Inc</TargetEntity></SourceEntity><SourceEntity id="24009" type="Company"><TargetEntity id="5000404102" type="organizationId">Schering-Plough Research Institute</TargetEntity></SourceEntity><SourceEntity id="1076" type="ciIndication"><TargetEntity id="10043607" type="MEDDRA"></TargetEntity><TargetEntity id="D013927" type="MeSH"></TargetEntity><TargetEntity id="304" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="158" type="ciIndication"><TargetEntity id="B20" type="ICD10"></TargetEntity><TargetEntity id="042" type="ICD9"></TargetEntity><TargetEntity id="10020161" type="MEDDRA"></TargetEntity><TargetEntity id="D015658" type="MeSH"></TargetEntity><TargetEntity id="-841965209" type="omicsDisease"></TargetEntity><TargetEntity id="862" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="325" type="ciIndication"><TargetEntity id="D013923" type="MeSH"></TargetEntity><TargetEntity id="-338631668" type="omicsDisease"></TargetEntity><TargetEntity id="306" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3258" type="ciIndication"><TargetEntity id="10051592" type="MEDDRA"></TargetEntity><TargetEntity id="D054058" type="MeSH"></TargetEntity><TargetEntity id="-489209930" type="omicsDisease"></TargetEntity><TargetEntity id="3262" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity></SourceEntity><SourceEntity id="312" type="Action"><TargetEntity id="3554" type="Mechanism">Platelet Adhesion Inhibitors</TargetEntity><TargetEntity id="3985" type="Mechanism">Drugs Targeting on PolyQ-expanded Proteins</TargetEntity></SourceEntity><SourceEntity id="11192" type="Action"><TargetEntity id="1024" type="Mechanism">PAR1 Antagonists</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Thromboembolism - US - Sep-2014</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="158">HIV infection</Indication><Indication id="325">Thromboembolism</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1076">Thrombosis</Indication><Indication id="3258">Acute coronary syndrome</Indication></IndicationsSecondary><ActionsPrimary><Action id="11192">Protease-activated receptor-1 antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="312">Platelet aggregation inhibitor</Action><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="751">Film coating</Technology><Technology id="595">Tablet formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="585">Oral formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra><Ephmra><Code>B1C</Code><Name>PLATELET AGGREGATION INHIBITORS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-03-28T13:16:50.000Z</LastModificationDate><ChangeDateLast>2019-02-08T00:00:00.000Z</ChangeDateLast><AddedDate>1999-08-04T16:07:24.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="18077" linkType="Company"&gt;Merck &amp;amp; Co&lt;/ulink&gt; (following its acquisition of &lt;ulink linkID="19711" linkType="Company"&gt;Schering-Plough&lt;/ulink&gt;)  has developed and launched vorapaxar (Zontivity; SCH-530348; MK-5348), an oral antagonist of the thrombin receptor (protease-activated receptor-1; PAR1); the product is marketed in the US by  Old API Wind-down (formerly Aralez Pharmaceuticals). In the US, vorapaxar is indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD) [&lt;ulink linkID="1556358" linkType="Reference"&gt;1556358&lt;/ulink&gt;], [&lt;ulink linkID="2117385" linkType="Reference"&gt;2117385&lt;/ulink&gt;]. In May 2018, the company was seeking to outlicense the US rights of the drug [&lt;ulink linkID="2031423" linkType="Reference"&gt;2031423&lt;/ulink&gt;&lt;/para&gt;&lt;para&gt;By September 2014, vorapaxar was launched in the US [&lt;ulink linkID="1598606" linkType="Reference"&gt;1598606&lt;/ulink&gt;]; in April 2017, Aralez relaunched the drug in the US [&lt;ulink linkID="1935123" linkType="Reference"&gt;1935123&lt;/ulink&gt;]. In January 2015, the drug coadministered with acetylsalicylic acid and, where appropriate, with &lt;ulink linkID="2836" linkType="Drug"&gt;clopidogrel&lt;/ulink&gt;, was approved in the EU  [&lt;ulink linkID="1638269" linkType="Reference"&gt;1638269&lt;/ulink&gt;]; in February 2016, launch was planned to commence later that year in certain undisclosed European countries [&lt;ulink linkID="1743025" linkType="Reference"&gt;1743025&lt;/ulink&gt;]. In June 2016, the EMA's CHMP recommended EU approval  to broaden the indication of vorapaxar for the reduction of atherothrombotic events in adult patients with a history of MI [&lt;ulink linkID="1776026" linkType="Reference"&gt;1776026&lt;/ulink&gt;]; however, in June 2017, the EU marketing authorization was withdrawn [&lt;ulink linkID="2135642" linkType="Reference"&gt;2135642&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2007, a phase III trial began in Japan for thrombosis [&lt;ulink linkID="842624" linkType="Reference"&gt;842624&lt;/ulink&gt;]; however, in November 2017, phase III development was discontinued in this territory for this indication [&lt;ulink linkID="1990497" linkType="Reference"&gt;1990497&lt;/ulink&gt;]. By November 2008, Schering-Plough was planning development of a fixed-dose combination of vorapaxar  and &lt;ulink linkID="2836" linkType="Drug"&gt;clopidogrel&lt;/ulink&gt; [&lt;ulink linkID="966270" linkType="Reference"&gt;966270&lt;/ulink&gt;]; however no development has been reported since that time.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;&lt;ulink linkID="PA2877271" linkType="Patent"&gt;WO-03089428&lt;/ulink&gt;, published in October 2003, claims naphtho[2,3-c]furan-3-one derivatives as thrombin receptor antagonists. &lt;ulink linkID="PA206005" linkType="Patent"&gt;WO-03033501&lt;/ulink&gt; and &lt;ulink linkID="PA147419" linkType="Patent"&gt;WO-0196330&lt;/ulink&gt;, published in April 2003 and December 2001, respectively, claim himbacine analogs as thrombin receptor antagonists. &lt;ulink linkID="IN2559101" linkType="Patent"&gt;WO-9926943&lt;/ulink&gt; published in June 1999 claims tricyclic compounds as thrombin receptor antagonists. In February 2013, Merck stated that the US compound patent for vorapaxar is scheduled to expire in 2024 [&lt;ulink linkID="1393396" linkType="Reference"&gt;1393396&lt;/ulink&gt;]; in Frebruary 2015, Merck noted that a Patent Term Restoration application was pending, which if granted, it would provide further protection until 2027 in the US [&lt;ulink linkID="1642667" linkType="Reference"&gt;1642667&lt;/ulink&gt;]; and in February 2016, the company also noted that the patent protection of the drug was eligible for a 6-month pediatric exclusivity extension [&lt;ulink linkID="1743025" linkType="Reference"&gt;1743025&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In April 2006, the FDA granted Fast Track designation to vorapaxar  [&lt;ulink linkID="662596" linkType="Reference"&gt;662596&lt;/ulink&gt;]. Filing expectations were delayed following changes to the TRA 2P trial in January 2011 [&lt;ulink linkID="1161171" linkType="Reference"&gt;1161171&lt;/ulink&gt;]. In July 2013, Merck reported that an NDA had been accepted for standard review by the FDA for the secondary prevention of cardiovascular events in patients with a history of heart attack and no history of stroke or transient ischemic attack  [&lt;ulink linkID="1456096" linkType="Reference"&gt;1456096&lt;/ulink&gt;]. By December 2013, a PDUFA date had been scheduled for January 15, 2014 [&lt;ulink linkID="1513399" linkType="Reference"&gt;1513399&lt;/ulink&gt;]. In January 2014, the FDA’s Cardiovascular and Renal Drugs Advisory Committee recommended approval of vorapaxar [&lt;ulink linkID="1515972" linkType="Reference"&gt;1515972&lt;/ulink&gt;]. In May 2014, US approval was granted for use of vorapaxar to reduce the risk of heart attack, stroke, cardiovascular death, and need for procedures to restore the blood flow to the heart in patients with a previous heart attack or blockages in the arteries to the legs  [&lt;ulink linkID="1554892" linkType="Reference"&gt;1554892&lt;/ulink&gt;],  [&lt;ulink linkID="1555818" linkType="Reference"&gt;1555818&lt;/ulink&gt;], [&lt;ulink linkID="1556156" linkType="Reference"&gt;1556156&lt;/ulink&gt;]; by September 2014, it had been launched in the US [&lt;ulink linkID="1598606" linkType="Reference"&gt;1598606&lt;/ulink&gt;]. In April 2017, Aralez  relaunched the drug in the US [&lt;ulink linkID="1935123" linkType="Reference"&gt;1935123&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In February 2013, Merck planned to file for European approval later that year, for the prevention of cardiovascular events in patients with a history of heart attack and no history of transient ischemic attack or stroke [&lt;ulink linkID="1393396" linkType="Reference"&gt;1393396&lt;/ulink&gt;]. In February 2014, the drug was listed as being under review in EU [&lt;ulink linkID="1536713" linkType="Reference"&gt;1536713&lt;/ulink&gt;]. In November 2014, the EMA's CHMP issued a positive opinion for the approval of vorapaxar for the reduction of atherothrombotic events [&lt;ulink linkID="1614874" linkType="Reference"&gt;1614874&lt;/ulink&gt;], [&lt;ulink linkID="1615311" linkType="Reference"&gt;1615311&lt;/ulink&gt;]. In January 2015, the drug coadministered with acetylsalicylic acid and, where appropriate, with &lt;ulink linkID="2836" linkType="Drug"&gt;clopidogrel&lt;/ulink&gt;, was approved in the EU for the reduction of atherothrombotic events in patients with a history of  MI [&lt;ulink linkID="1638269" linkType="Reference"&gt;1638269&lt;/ulink&gt;]. In February 2016, launch was planned to commence later that year in certain undisclosed European countries [&lt;ulink linkID="1743025" linkType="Reference"&gt;1743025&lt;/ulink&gt;]. In June 2016, the EMA's CHMP adopted a positive opinion for an extension to the existing indication of  vorapaxar for the reduction of atherothrombotic events in adult patients with a history of MI [&lt;ulink linkID="1776026" linkType="Reference"&gt;1776026&lt;/ulink&gt;]; however, in June 2017, the EU marketing authorization was withdrawn [&lt;ulink linkID="2135642" linkType="Reference"&gt;2135642&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2016, the Paediatric Committee (PDCO) adopted positive opinion to an agreed pediatric investigation plan for the prevention of arterial thromboembolism [&lt;ulink linkID="1750632" linkType="Reference"&gt;1750632&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In November 2018, the product was granted "Clinically Urgent Foreign Drug" in China [&lt;ulink linkID="2089481" linkType="Reference"&gt;2089481&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;In May 2016, the drug was approved in Canada as Zontivity [&lt;ulink linkID="1772444" linkType="Reference"&gt;1772444&lt;/ulink&gt;]. By March 2019, the product has still not been launched in Canada [&lt;ulink linkID="2135649" linkType="Reference"&gt;2135649&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SAFETY INFORMATION&lt;/subtitle&gt;The US label for vorapaxar contains a boxed warning highlighting an increased risk of bleeding, including life-threatening and fatal bleeding [&lt;ulink linkID="1554892" linkType="Reference"&gt;1554892&lt;/ulink&gt;], [&lt;ulink linkID="1556358" linkType="Reference"&gt;1556358&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Prevention of cardiac events in ACS&lt;/subtitle&gt;In December 2007, a randomized, double-blinded, placebo-controlled phase III study (&lt;ulink linkID="4439" linkType="Protocol"&gt;NCT00527943&lt;/ulink&gt;; TRACER; P04736) was initiated. The hospital-based trial was to enroll an estimated 12,500 patients with non-ST segment elevation ACS, who were to receive standard medical care with or without vorapaxar, given as a 40 mg loading dose followed by 2.5 mg maintenance dosing. The primary endpoint was the composite of cardiovascular death, MI, rehospitalization for ACS, urgent coronary revascularization or stroke. The composite of cardiovascular death, MI or stroke was the secondary endpoint [&lt;ulink linkID="785446" linkType="Reference"&gt;785446&lt;/ulink&gt;], [&lt;ulink linkID="842628" linkType="Reference"&gt;842628&lt;/ulink&gt;]. By July 2010, patient enrollment of more than 12,500 patients in the main component of the trial had been completed [&lt;ulink linkID="1120140" linkType="Reference"&gt;1120140&lt;/ulink&gt;]. By January 2011, the DSMB had completed a review of available data. At that time, the predefined number of primary and major secondary endpoints had been accumulated but not all patients would receive treatment through the prespecified one-year follow-up [&lt;ulink linkID="1161171" linkType="Reference"&gt;1161171&lt;/ulink&gt;], [&lt;ulink linkID="1162243" linkType="Reference"&gt;1162243&lt;/ulink&gt;]. In November 2011, data were presented at the American Heart Association Scientific Sessions in Orlando, FL. The trial did not meet the primary endpoint; vorapaxar plus standard of care resulted in a non-significant reduction in the first occurrence of any component of the composite of cardiovascular (CV) death, myocardial infarction (MI), stroke, recurrent ischemia with re-hospitalization and urgent coronary revascularization compared with placebo plus standard of care. In addition, rates of bleeding and intracranial hemorrhage were significantly higher in vorapaxar-treated patients  [&lt;ulink linkID="1239226" linkType="Reference"&gt;1239226&lt;/ulink&gt;], [&lt;ulink linkID="1239259" linkType="Reference"&gt;1239259&lt;/ulink&gt;], [&lt;ulink linkID="1241653" linkType="Reference"&gt;1241653&lt;/ulink&gt;]. Similar data were also published in January 2012 [&lt;ulink linkID="1239600" linkType="Reference"&gt;1239600&lt;/ulink&gt;].  In March 2012, sub-analysis data were presented at the 61st ACC meeting in Chicago, IL. A substudy in 249 patients, mostly on dual antiplatelet therapy, were assessed for platelet aggregation by 20 microM ADP, 15 microM thrombin receptor agonist peptide (TRAP) and a cocktail combination of 2.5 microg/ml collagen-related peptide, 5 microM ADP and 15 microM TRAP. Vorapaxar rapidly and strongly inhibited TRAP-induced platelet aggregation from 2 h post-treatment onwards compared to placebo, but had a minor nonsignificant inhibitory effect on ADP-induced aggregation. An intermediate but significant effect was observed using the aggregation cocktail [&lt;ulink linkID="1275821" linkType="Reference"&gt;1275821&lt;/ulink&gt;]. Further TRACER data were reported in August 2012 at the 2012 ESC Congress in Munich, Germany. At 24 months, the event rates for primary endpoints of CV death, MI, stroke, hospitalization for ischemia and urgent revascularization were 19.9 and 18.5% for placebo and vorapaxar, respectively [&lt;ulink linkID="1317815" linkType="Reference"&gt;1317815&lt;/ulink&gt;]. The incidence rate of major ischemic events increased with increased risk of bleeding in a non-linear manner; however, no enhanced vorapaxar efficacy was observed in patients with a higher bleeding risk. In fact, increased bleeding with vorapaxar was observed in those patients at higher risk of bleeding [&lt;ulink linkID="1317533" linkType="Reference"&gt;1317533&lt;/ulink&gt;]. Data from a subgroup analysis in ACS patients undergoing coronary artery bypass graft (CABG)  surgery(n = 1312) were also presented. A reduction in the primary endpoint measures of 45% was reported for patients on vorzpaxar compared with placebo [&lt;ulink linkID="1317620" linkType="Reference"&gt;1317620&lt;/ulink&gt;]. In November 2012, further data from the sub-group analysis were presented at the AHA Scientific Sessions in Los Angeles, CA. Among medically managed patients  and  those who had invasive treatment  in the vorapaxar (n = 2091) and placebo (n = 2103) groups, the rates of CV death, MI, stroke, hospitalization with ischemia, and urgent revascularization were similar [&lt;ulink linkID="1337895" linkType="Reference"&gt;1337895&lt;/ulink&gt;]. In the vorapaxar and placebo groups, the rates of CV death, MI, stroke, hospitalization with ischemia, and urgent revascularization  in patients who underwent and who did not undergo PCI, were also similar.  In patients with bare-metal stent implanted, the efficacy of vorapaxar was found to be larger with 30% reduction in CV death, Mi, and stroke [&lt;ulink linkID="1337900" linkType="Reference"&gt;1337900&lt;/ulink&gt;]. In November 2013, further data were presented at the AHA Scientific Sessions in Dallas, TX. Significant association of CYP2C19 genotypes and serum paraoxonase/arylesterase 1 activity was not observed with long-term ischemic outcomes, and changes in vorapaxar efficacy were not observed [&lt;ulink linkID="1497096" linkType="Reference"&gt;1497096&lt;/ulink&gt;].  In November 2013, further data were presented at the same conference.  Age did not significantly influence the efficacy and safety of vorapaxar [&lt;ulink linkID="1496985" linkType="Reference"&gt;1496985&lt;/ulink&gt;]. In November 2013, post-hoc analysis data were presented at the same conference. Treatment with vorapaxar did not reduce risk of cardiovascular death, myocardial infarction, or stroke and increased the risk of moderate or severe bleeding irrespective of PAD status [&lt;ulink linkID="1496917" linkType="Reference"&gt;1496917&lt;/ulink&gt;]. In  November 2014, similar data were presented at the AHA Scientific Sessions in Chicago, IL [&lt;ulink linkID="1613496" linkType="Reference"&gt;1613496&lt;/ulink&gt;].  Further data were presented   at the same conference. No difference was observed for the primary composite endpoint (3.4 versus 3.9%; p = 0.41) and in the incidence of non-cardiac surgery bleeding (3.9 versus 3.4%; p = 0.17) or or Global Use of Strategies to Open Occluded Arteries (GUSTO) moderate/severe bleeding (4.2 versus 3.7%; p = 0.55) in vorapaxar versus placebo groups at 30 days [&lt;ulink linkID="1612026" linkType="Reference"&gt;1612026&lt;/ulink&gt;]. In March 2015, similar clinical data were presented at the 249th ACS meeting in Denver, CO [&lt;ulink linkID="1642419" linkType="Reference"&gt;1642419&lt;/ulink&gt;]. In June 2016, data were presented at the 2016 WCC in Mexico City, Mexico, showing that in 75 patients from this trial no significant of effects of vorapaxar on PTX3 was observed [&lt;ulink linkID="1777865" linkType="Reference"&gt;1777865&lt;/ulink&gt;]. In November 2018, further data were presented at the were presented at the 2018 AHA Scientific Sessions in Chicago, IL. Incidence of any hemorrhagic stroke was 15.1%, any non-hemorrhagic stroke  was 83.9% and any stroke of uncertain type was 2%. In the vorapaxar versus placebo groups, the number of patients reported with severe disability were 2  and  0; moderate disability were 5  and 8 and no symptoms were 10 and 13, respectively [&lt;ulink linkID="2091595" linkType="Reference"&gt;2091595&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2006, a Japanese, double-blind, placebo-controlled phase II trial (&lt;ulink linkID="15614" linkType="Protocol"&gt;NCT00684203&lt;/ulink&gt;; P04772) was initiated in patients (estimated n = 120) with ACS, who were to be randomized 4:1 to vorapaxar plus standard of care (&lt;ulink linkID="51800" linkType="Drug"&gt;aspirin&lt;/ulink&gt;, ticlodipine, or heparin) or standard of care alone, and treated for 60 days [&lt;ulink linkID="905535" linkType="Reference"&gt;905535&lt;/ulink&gt;], [&lt;ulink linkID="1022101" linkType="Reference"&gt;1022101&lt;/ulink&gt;]. In October 2007, results were released showing that vorapaxar does not increase the rate of major or minor bleeding in patients with ACS or prior ischemic stroke when added to standard antiplatelet therapy. The drug also showed significant reduction in peri-procedural MIs in the ACS study patients undergoing percutaneous coronary intervention (PCI). The overall incidence of adverse events was similar across treatment arms [&lt;ulink linkID="841866" linkType="Reference"&gt;841866&lt;/ulink&gt;]. In August 2009, similar data, presumed to be from this trial, were presented at the AIMECS 09 conference in Cairns, Australia [&lt;ulink linkID="1036417" linkType="Reference"&gt;1036417&lt;/ulink&gt;], [&lt;ulink linkID="1036396" linkType="Reference"&gt;1036396&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2005, a randomized, double-blind, placebo-controlled, dose-ranging phase II study (&lt;ulink linkID="4538" linkType="Protocol"&gt;NCT00132912&lt;/ulink&gt;; P03573; TRA-PCI) was initiated to assess oral loading  and maintenance doses of vorapaxar sulfate. The trial enrolled 1030 patients randomized to one of three oral loading doses of vorapaxar  (10, 20 or 40 mg) plus standard of care (&lt;ulink linkID="2836" linkType="Drug"&gt;clopidogrel&lt;/ulink&gt; plus aspirin) or placebo plus standard of care. Patients who received a vorapaxar loading dose and subsequently underwent PCI (n = 573) were randomized to one of three oral daily maintenance doses of vorapaxar sulfate(0.5 mg, 1.0 mg, 2.5 mg). Patients who received placebo were randomized to receive standard of care alone. The total duration of treatment was 60 days, and patients were followed for an additional 60 days post-treatment. The primary endpoint was incidence of bleeding; secondary endpoints included the incidence of death and major adverse events. The study was completed in January 2007 [&lt;ulink linkID="1017544" linkType="Reference"&gt;1017544&lt;/ulink&gt;]. In March 2007, at the American College of Cardiology in New Orleans, LA, data were reported from the trial. The primary endpoint was met (no increase in major and minor bleeding). Although the trial was not powered to show efficacy, the highest dose of the drug reduced cardiovascular events by 46%, and MI was seen to decrease by 52% with 40 mg and 41% overall. Incidence of major or minor bleeding in the vorapaxar arms was 2.8%, compared with 3.3% in for standard care alone. The incidence of death or major adverse cardiac event was 8.6% in the placebo group, and 5.9% in the vorapaxar arm [&lt;ulink linkID="777547" linkType="Reference"&gt;777547&lt;/ulink&gt;]. In a pharmacokinetic analysis of the TRA-PCI trial, presented at AHA in December 2007, the loading doses of 10, 20 or 40 mg vorapaxar achieved &amp;gt; 90% inhibition of platelet aggregation 60  to 120 min post dose, with 40 mg achieving &amp;gt; 90% inhibition between 60 and 90 min. Vorapaxar  patients who received maintenance doses of 0.5, 1.0 or 2.5 mg exhibited &amp;gt; 90% IPA at 30 and 60 days. Vorapaxar had no significant effects on ADP, collagen or AA-induced platelet aggregation compared with placebo [&lt;ulink linkID="848763" linkType="Reference"&gt;848763&lt;/ulink&gt;]. In March 2009, further results were published, showing patients treated with vorapaxar had a much higher thrombin-receptor agonist peptide (TRAP)-induced platelet inhibition compared with standard care alone [&lt;ulink linkID="991379" linkType="Reference"&gt;991379&lt;/ulink&gt;], [&lt;ulink linkID="991548" linkType="Reference"&gt;991548&lt;/ulink&gt;]. In July 2009, these data were presented at the XXII ISTH Congress in Boston, MA [&lt;ulink linkID="1029223" linkType="Reference"&gt;1029223&lt;/ulink&gt;]. In February 2010, similar data were presented at CHI's 17th Molecular Medicine Tri-Conference in San Francisco, CA [&lt;ulink linkID="1075900" linkType="Reference"&gt;1075900&lt;/ulink&gt;]. In June 2010, similar data were presented at the 32nd NMCS meeting in Minneapolis, MN [&lt;ulink linkID="1101027" linkType="Reference"&gt;1101027&lt;/ulink&gt;]. In August 2011, similar data were presented at the 242nd ACS meeting in Denver, CO [&lt;ulink linkID="1214048" linkType="Reference"&gt;1214048&lt;/ulink&gt;]. In March 2015, similar clinical data were presented at the 249th ACS meeting in Denver, CO [&lt;ulink linkID="1642419" linkType="Reference"&gt;1642419&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Prevention of cardiac events in prior stroke, MI or PAD&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In July 2008, a phase III study (&lt;ulink linkID="56782" linkType="Protocol"&gt;NCT00617123&lt;/ulink&gt;; P05183AM1; P05183) began in patients (n = 200) with a history of atherosclerosis involving the coronary, cerebral, or peripheral vascular system. The randomized, double-blind, placebo-controlled study was to evaluate the ocular safety of the vorapaxar (2.5 mg qd for 1 year) in a subset of patients participating in the NCT00526474 (TRA 2P) study. The primary endpoint was incidence of vacuolization in the inner nuclear layer of the retina through treatment and follow-up. The study was completed in October 2010 [&lt;ulink linkID="967153" linkType="Reference"&gt;967153&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2007, a randomized, double-blind, placebo-controlled phase III trial (&lt;ulink linkID="4441" linkType="Protocol"&gt;NCT00526474&lt;/ulink&gt;; P04737; TRA 2P-TIMI 50) began. The trial was to enroll patients (n = 26,447) with prior MI or stroke or existing peripheral arterial disease who would receive standard medical care with or without 2.5 mg maintenance dosing of vorapaxar sulfate in the chronic care setting. The composite of cardiovascular death, MI, urgent coronary revascularization or stroke was the primary endpoint, and the secondary endpoint was cardiovascular death, MI or stroke. Enrollment was completed in November 2009 and the study was expected to complete in December 2011  [&lt;ulink linkID="785446" linkType="Reference"&gt;785446&lt;/ulink&gt;], [&lt;ulink linkID="842624" linkType="Reference"&gt;842624&lt;/ulink&gt;], [&lt;ulink linkID="1066620" linkType="Reference"&gt;1066620&lt;/ulink&gt;]. By January 2011,  the DSMB had completed a review of available data. Following recommendations from the DSMB, Merck was to continue the study in patients who had experienced a previous heart attack or peripheral arterial disease (approximately 75% of the patients enrolled in the study), but would discontinue treatment in patients who had experienced a stroke prior to or during the trial. This was because the DSMB had observed an increase in intracranial hemorrhage in patients with a history of stroke that was not outweighed by their considerations of potential benefit  [&lt;ulink linkID="1161171" linkType="Reference"&gt;1161171&lt;/ulink&gt;], [&lt;ulink linkID="1162243" linkType="Reference"&gt;1162243&lt;/ulink&gt;], [&lt;ulink linkID="1172264" linkType="Reference"&gt;1172264&lt;/ulink&gt;]. In February 2012, topline data were reported. Patients treated with vorapaxar in combination with standard medical care achieved significant reductions in cardiovascular death, MI, stroke or urgent coronary revascularization compared with those in the standard medical care alone arm. There was a significant increase in bleeding, including intracranial hemorrhage (ICH), among patients taking vorapaxar in addition to standard of care, although there was a lower risk of ICH in patients without a history of stroke [&lt;ulink linkID="1260766" linkType="Reference"&gt;1260766&lt;/ulink&gt;]. In March 2012, further results were published and presented at the 61st ACC meeting in Chicago, IL. In patients who had experienced a heart attack, the relative risk of CV death, heart attack or stroke was reduced by 20% (8.1  versus 9.7%, respectively) at three years for the vorapaxar  group compared with standard of care alone; in this patient group, the rate of heart attacks was reduced by 17% in the vorapaxar group compared with standard of care alone (5.2 versus 6.1%, respectively) [&lt;ulink linkID="1274343" linkType="Reference"&gt;1274343&lt;/ulink&gt;], [&lt;ulink linkID="1274585" linkType="Reference"&gt;1274585&lt;/ulink&gt;], [&lt;ulink linkID="1275821" linkType="Reference"&gt;1275821&lt;/ulink&gt;]. In June 2012,  data from a subset of patients with peripheral arterial disease (n = 3787) were presented in the American Heart Association's Emerging Science Series webinar. In this patient group, no significant difference was observed between the vorapaxar and placebo treatment groups for reduction in major cardiovascular events. However, fewer vorapaxar-treated patients were hospitalized for blood clots in the limb or required revascularization procedures compared with the placebo group. Moderate and severe bleeding were more frequent in the vorapaxar group; however there was no increase in fatal bleeding   [&lt;ulink linkID="1302929" linkType="Reference"&gt;1302929&lt;/ulink&gt;]. In November 2012,  secondary analysis data from 26449 patients were presented at the AHA Scientific Sessions in Los Angeles, CA. Specifically, in the vorapaxar group as compared with the placebo group, significantly lower rates of revascularization were seen for both peripheral (3.9 versus 5.2%) and coronary vascular beds (9.7 versus 10.4%), including reduced coronary artery bypass grafting rates (1.7 versus 2%) [&lt;ulink linkID="1337903" linkType="Reference"&gt;1337903&lt;/ulink&gt;]. Further data  were also presented at the same conference in the same month showing that  in MI or PAD patients with no history of cardiovascular disease, ischemic stroke incidences were significantly decreased with vorapaxar-treatment [&lt;ulink linkID="1337906" linkType="Reference"&gt;1337906&lt;/ulink&gt;]; a total of 40, 44 and 16% of patients received &amp;lt; 100, 100 to 162 mg, and &amp;gt; 162 mg aspirin daily, and in these patients,  vorapaxar effect was similar with approximately 20% reductions in the risk of cardiovascular (CV) death/myocardial infarction (MI)/stroke and CV death/MI [&lt;ulink linkID="1337899" linkType="Reference"&gt;1337899&lt;/ulink&gt;]; and planned thienopyridine therapy and after adjustment for qualifying disease state  had no impact on the effect of vorapaxar on the primary endpoint [&lt;ulink linkID="1337901" linkType="Reference"&gt;1337901&lt;/ulink&gt;]. In November 2014, further clinical data were  presented  in patients (n = 20,170) with acute coronary syndrome at the AHA Scientific Sessions in Chicago, IL. Lower rates of cardiovascular disease, MI, or stroke and similar rates of severe bleeding occurred in the vorapaxar group compared to placebo, as measured using a landmark analysis through 7 days after acute coronary syndrome [&lt;ulink linkID="1612040" linkType="Reference"&gt;1612040&lt;/ulink&gt;]. In March 2015, post-hoc subgroup analyses were presented at the  	64th American College of Cardiology Annual Scientific Sessions in San Diego, CA. In symptomatic PAD patients, vorapaxar plus aspirin and/or &lt;ulink linkID="2836" linkType="Drug"&gt;clopidogrel&lt;/ulink&gt; gave a 42% relative risk reduction in acute limb ischemia (ALI) incidence compared with aspirin and/or clopidogrel alone. In patients with a history of PAD, vorapaxar reduced the need for peripheral revascularization. In post-MI or PAD patients with no stroke or TIA history who had undergone prior CABG, vorapaxar reduced the risk of CV death, myocardial infarction or stroke compared with placebo (11.9 versus 15.6%)    [&lt;ulink linkID="1639045" linkType="Reference"&gt;1639045&lt;/ulink&gt;], [&lt;ulink linkID="1644566" linkType="Reference"&gt;1644566&lt;/ulink&gt;], [&lt;ulink linkID="1644567" linkType="Reference"&gt;1644567&lt;/ulink&gt;], [&lt;ulink linkID="1647894" linkType="Reference"&gt;1647894&lt;/ulink&gt;]. In March 2015, similar clinical data were presented at the 249th ACS meeting in Denver, CO [&lt;ulink linkID="1642419" linkType="Reference"&gt;1642419&lt;/ulink&gt;]. In September 2015, similar data were presented at the 2015 FMC in Antwerp, Belgium  [&lt;ulink linkID="1696146" linkType="Reference"&gt;1696146&lt;/ulink&gt;]. In November 2017, further data in patients with impaired renal function (n = 19993) were presented at the 2017 AHA Scientific Sessions in Anaheim, CA. At 30 months, in overall, Q1 (&amp;lt; 68 ml/min/1.73 m2), Q2 (69 to 80 ml/min/1.73 m2), Q3 (80 to 94 ml/min/1.73 m2) and Q4 (&amp;gt; 94 ml/min/1.73 m2) quartiles, vorapaxar reduced the risk of MACE by 20 (p = 0.07), 14, 23, 26 and 21%, respectively. Regardless of the baseline renal function, vorapaxar increased the risk of GUSTO moderate or severe bleeding (p = 0.54). At 30 months, in overall, Q1, Q2, Q3 and Q4 quartiles, vorapaxar reduced the risk of net clinical outcome (cardiovascular death, myocardial infarction, stroke or GUSTO severe bleeding) by 18, 13, 17, 28 and 18%, respectively  [&lt;ulink linkID="1980644" linkType="Reference"&gt;1980644&lt;/ulink&gt;]. In August 2018, results from a biomarker analysis (n = 135) were presented at the 2018 ESC Congress in Munich, Germany. In the vorapaxar and placebo groups, median level of soluble P-selectin was 24.9 and 29.3 ng/ml (p = 0.03), factor IXa-antithrombin was 86.7 and 85.4 pM (p = 0.95), factor Xa-antithrombin was 282.1 and 291.4 pM (p = 0.14) and thrombin-antithrombin was 4 and 3.8 ng/ml (p = 0.71), respectively [&lt;ulink linkID="2065678" linkType="Reference"&gt;2065678&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In December 2006, a double-blind, placebo-controlled phase II study (&lt;ulink linkID="15605" linkType="Protocol"&gt;NCT00684515&lt;/ulink&gt;; P05005) was initiated in Japan, in patients (estimated n = 93) with prior ischemic stroke. Patients were to be randomized 2:1 to vorapaxar plus standard of care therapy (aspirin and thienopyridine) or standard of care alone, and treated for 60 days. The study was completed in October 2007 [&lt;ulink linkID="1105780" linkType="Reference"&gt;1105780&lt;/ulink&gt;]. Data from 90 patients demonstrated that vorapaxar in addition to standard antiplatelet therapy induced no increase in the rate of major or minor TIMI bleeding compared with placebo [&lt;ulink linkID="1022100" linkType="Reference"&gt;1022100&lt;/ulink&gt;], [&lt;ulink linkID="1026945" linkType="Reference"&gt;1026945&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In August 2010, a 173-patient, phase I, randomized, open-label, crossover study (&lt;ulink linkID="77678" linkType="Protocol"&gt;NCT01358344&lt;/ulink&gt;; P06558) was initiated in the US, to determine the bioequivalence of vorapaxar (2.5 mg) tablets containing a high (approximately 46%) and low (approximately 23%)  percentage of the active pharmaceutical ingredient as the free base within the range used in the pivotal phase III trials. The study was completed in December 2010 [&lt;ulink linkID="1205428" linkType="Reference"&gt;1205428&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2005, data from a phase I trial were reported at the 2005 AHA meeting in Dallas, TX. The randomized, evaluator blinded, placebo-controlled, ascending dose, parallel group study was conducted in 50 healthy men aged between 18 and 40 years, who were enrolled into one of six groups (n = 7 to 9/group) and randomized (3:1 active to placebo) to receive oral vorapaxar (0.25, 1, 5, 10, 20 or 40 mg) or placebo. The drug caused significant dose-related inhibition of TRAP-induced platelet aggregation with greater than 90% inhibition at 1 h at the 20 and 40 mg doses; at doses of greater than or equal to 5 mg this inhibition was maintained for at least 72 h. All doses were well tolerated and reported adverse effects were generally mild and non-specific [&lt;ulink linkID="634216" linkType="Reference"&gt;634216&lt;/ulink&gt;]. In February 2010, similar data were presented at CHI's 17th Molecular Medicine Tri-Conference in San Francisco, CA [&lt;ulink linkID="1075900" linkType="Reference"&gt;1075900&lt;/ulink&gt;]. In March 2015, similar clinical data were presented at the 249th ACS meeting in Denver, CO [&lt;ulink linkID="1642419" linkType="Reference"&gt;1642419&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2003, phase I trials of an undisclosed lead in ischemic complications, later presumed to be vorapaxar sulfate, had been initiated [&lt;ulink linkID="513822" linkType="Reference"&gt;513822&lt;/ulink&gt;]; early clinical studies for this indication were ongoing in February 2004 [&lt;ulink linkID="559079" linkType="Reference"&gt;559079&lt;/ulink&gt;]. In March 2009, at the 237th ACS meeting in Salt Lake City, UT, data were presented showing that vorapaxar produced no severe adverse events in phase I studies [&lt;ulink linkID="987486" linkType="Reference"&gt;987486&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other studies&lt;/subtitle&gt;In September 2015, a randomized, double-blind, parallel assigned, phase I/II trial (&lt;ulink linkID="224951" linkType="Protocol"&gt;NCT02394730&lt;/ulink&gt;, 2014-01-ADV, 2013 bench to bedside grant) was initiated in the US and Australia, to compare the safety and efficacy of vorapraxar versus placebo for the treatment of  HIV associated inflammation and coagulopathy in patients  (expected n = 60)  with well controlled HIV replication. At that time, the trial was expected to complete in November 2016. In June 2017, the study was ongoing, and at that time was expected to complete in December 2017 [&lt;ulink linkID="1736961" linkType="Reference"&gt;1736961&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2012,  data from two open-label, two treatment parallel-group, single-center studies were presented at the 113th Annual Meeting of the ASCPT in National Harbor, MD. Chinese subjects (n = 28) and US subjects (n = 37) single dose of vorapaxar (40 and 120 mg, respectively) or qd dose of 2.5 mg vorapaxar. The peak concentrations of the metabolite after single dose of vorapaxar were achieved at a median Tmax value of 24 and 18 h for Chinese and US subjects, respectively; and after daily doses of vorapaxar, the peak concentrations of the metabolite were achieved at a median Tmax of 4 h in both Chinese and US subjects. The t1/2 value was similar for vorapaxar and its metabolite.   Vorapaxar was well tolerated [&lt;ulink linkID="1270253" linkType="Reference"&gt;1270253&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2012,  data from a randomized, placebo- and positive-controlled, double-blind, open-label, parallel-group study were presented at the 113th Annual Meeting of the ASCPT in National Harbor, MD. Healthy men and women (n = 40 in each group, aged 18 to 50 years) received a single oral dose of vorapaxar (120 mg), &lt;ulink linkID="12978" linkType="Drug"&gt;moxifloxacin&lt;/ulink&gt; or placebo. The time matched baseline corrected Fridericia's QTc (QTcF) interval difference between vorapaxar and placebo groups was observed to be substantially below the threshold of regulatory concern. Treatment with vorapaxar showed no increase in the QT/QTc interval length, while moxifloxacin (positive control) did increase the interval length. The geometric mean Cmax (708 ng/ml) and AUC(0 to 24) (6607 ng.h/ml) value of vorapaxar (120 mg) was found to be approximately 10- and 6-fold greater than the steady state exposure of 2.5 mg of maintenance dose, respectively.  Vorapaxar was well tolerated [&lt;ulink linkID="1269853" linkType="Reference"&gt;1269853&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Miscellaneous Studies&lt;/subtitle&gt;In June 2015, the company planned to initiate a double-blind, randomized, placebo controlled, pilot phase II trial (&lt;ulink linkID="233583" linkType="Protocol"&gt;NCT02475837&lt;/ulink&gt;; 33763) to evaluate the safety and efficacy of vorapaxar in maturation of arteriovenous fistulae for hemodialysis access, in August 2015 in 128 patients. The study was expected to complete in February 2017 [&lt;ulink linkID="1675737" linkType="Reference"&gt;1675737&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In September 2015, preclinical data were presented at the 2015 FMC in Antwerp, Belgium. Carbamate derivatives upon further optimization of the drug was potent in human platelet-derived PAR1 radioligand (3[H]haTRAP) assay. In human coronary smooth muscle cells, it inhibited thrombin-induced calcium transient ( Ki = 1.1 nM) and thrombin-stimulated thymidine incorporation (Ki = 13 nM). It was particularly selective against PAR2, PAR3 and PAR4. In rat and monkey, vorapaxar (10 and 1 mg/kg, respectively, po) was well absorbed (68 and 82%), had elimination t1/2 of 5.1 and 13 h and oral bio-availability of 33 and 86%, respectively [&lt;ulink linkID="1696146" linkType="Reference"&gt;1696146&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2015, preclinical data were presented at the 249th ACS meeting in Denver, CO. SCH-530348 (0.1 mg/kg, po) showed a long duration of action in ex vivo and inhibited the platelet aggregation for &amp;gt; 48 h and it was 30-fold more potent when compared with SCH-205831 [&lt;ulink linkID="1642419" linkType="Reference"&gt;1642419&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In February 2010, preclinical data were presented at CHI's 17th Molecular Medicine Tri-Conference in San Francisco, CA. Vorapaxar had good PK characteristics in rat and monkey, and was potent when tested in the monkey ex 	It was still fully active after 24 h but platelet function was shown to recover in the 48-h range after a single oral dose [&lt;ulink linkID="1075900" linkType="Reference"&gt;1075900&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2009,  data were presented at the AIMECS 09 conference in Cairns, Australia. Vorapaxar  had a Ki value of 8.5 nM for the PAR1 receptor. In rat and monkey it had a half-life of 5 and 10 h, respectively, when administered iv [&lt;ulink linkID="1036417" linkType="Reference"&gt;1036417&lt;/ulink&gt;], [&lt;ulink linkID="1036396" linkType="Reference"&gt;1036396&lt;/ulink&gt;]. In August 2011, similar preclinical data were presented at the 242nd ACS meeting in Denver, CO [&lt;ulink linkID="1214048" linkType="Reference"&gt;1214048&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2008,  data were presented at the AHA Scientific Sessions in New Orleans, LA. Pharmacological characteristics of the drug were assessed in vitro in human cell cultures and ex vivo in cynomolgus monkeys. Vorapaxar showed a high affinity for PAR-1 receptor, and led to complete and sustained inhibition of TRAP-induced ex vivo platelet aggregation for 24 h. Furthermore, significant inhibition was maintained for 48 h [&lt;ulink linkID="957538" linkType="Reference"&gt;957538&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2007, preclinical data were presented at the AHA Scientific Sessions in Orlando, FL. Vorapaxar was found to be a potent and selective inhibitor of PAR1 activity, and demonstrated a predictable pharmacokinetic profile [&lt;ulink linkID="850762" linkType="Reference"&gt;850762&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2005,  data were presented at the 229th ACS meeting in San Diego, CA. This compound exhibited an improved pharmacokinetic profile than previously identified leads, including an improved aqueous solubility. Vorapaxar also demonstrated 100% thrombin inhibition in a 24-h period from an oral dose of 1 mg/kg and appeared efficacious in a primate model of thrombosis [&lt;ulink linkID="589514" linkType="Reference"&gt;589514&lt;/ulink&gt;], [&lt;ulink linkID="587669" linkType="Reference"&gt;587669&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other compounds&lt;/subtitle&gt;By November 2003, a series of orally active thrombin receptor antagonists that inhibit platelet aggregations without bleeding liability had been identified [&lt;ulink linkID="513822" linkType="Reference"&gt;513822&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A series of benzimidazole thrombin receptor antagonists were reported in October 2001. The most active compound from the series displayed an IC50 value of 33 nM at PAR-1 and an IC50 value of 1500 nM for thrombin-induced platelet aggregation [&lt;ulink linkID="425949" linkType="Reference"&gt;425949&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 1999, SAR studies were published on a series of small molecule pyrroloquinoline thrombin receptor antagonists. The lead compound had a thrombin receptor IC50 value of 300 nM and an aggregation IC50 value of 3000 nM. The two most potent analogs had IC50 values of 56 and 52 nM [&lt;ulink linkID="335120" linkType="Reference"&gt;335120&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;Vorapaxar is also referred to as thrombin receptor antagonist (TRA) [&lt;ulink linkID="1023091" linkType="Reference"&gt;1023091&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;Julie Oestreich, &lt;ulink linkType="Company" linkID="20600"&gt;University of Kentucky&lt;/ulink&gt;, Lexington, USA&lt;/para&gt;&lt;para&gt;Submission date:17 June 2009&lt;br/&gt;Publication date: 02 September 2009&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Abstract&lt;/subtitle&gt;SCH-530348 is a novel antiplatelet agent undergoing development by &lt;ulink linkType="Company" linkID="19711"&gt;Schering-Plough Corp&lt;/ulink&gt; for the treatment and prevention of atherothrombosis. The compound is an orally administered himbacine analog that potently antagonizes the platelet thrombin receptor protease-activated receptor 1, which leaves the procoagulant function of thrombin intact. In preclinical studies, SCH-530348 demonstrated no effect on bleeding time or coagulation parameters. In both cynomolgus monkeys and humans, the compound had high bioavailability and inhibited ex vivo TRAP (thrombin receptor-activating peptide)-stimulated platelet aggregation in a potent and long-lasting manner. In a phase II clinical trial of patients undergoing percutaneous coronary intervention, SCH-530348 added to standard therapy with &lt;ulink linkType="Drug" linkID="51800"&gt;aspirin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt; did not increase major or minor thrombolysis in myocardial infarction bleeding, and demonstrated a trend toward decreased major adverse cardiovascular events versus placebo. At the time of publication, three phase III trials were underway to assess the efficacy and safety of SCH-530348 for at least 1 year in up to 35,000 patients with acute coronary syndromes or atherosclerosis. The distinct mechanism of action of SCH-530348 allows for cardiovascular protection without the liability of increased bleeding associated with other antiplatelet therapies. Phase III trials in high-risk patients will determine the use of SCH-530348 in cardiological practice.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide [&lt;ulink linkType="Reference" linkID="1024352"&gt;1024352&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1024353"&gt;1024353&lt;/ulink&gt;]. The disease has previously been associated with high-income countries; however, in 2003, 80% of cardiovascular-related deaths occurred in low- and middle-income countries [&lt;ulink linkType="Reference" linkID="1024352"&gt;1024352&lt;/ulink&gt;]. The WHO estimated that CVD will become the leading cause of death in developing nations by 2010 [&lt;ulink linkType="Reference" linkID="1024354"&gt;1024354&lt;/ulink&gt;]. High-prevalence risk factors for CVD, such as underlying coronary artery disease or atherosclerosis (ie, plaque build-up inside the coronary arteries), smoking, a high-fat diet, hypertension or diabetes, often cause damage to the vascular endothelium [&lt;ulink linkType="Reference" linkID="1024353"&gt;1024353&lt;/ulink&gt;]. As a result, millions of individuals worldwide are at risk for plaque disruption leading to acute cardiac events, including coronary artery occlusion and arterial thrombosis (ie, the formation of a blood clot [thrombus] inside a blood vessel that obstructs blood flow) [&lt;ulink linkType="Reference" linkID="1024353"&gt;1024353&lt;/ulink&gt;]. Such events result in stenosis (ie, narrowing of blood vessels) and can lead to acute coronary syndromes such as unstable angina and myocardial infarction, and other conditions such as stroke [&lt;ulink linkType="Reference" linkID="1024353"&gt;1024353&lt;/ulink&gt;]. In the US, CVD complications that required inpatient procedures, such as cardiac catheterization, percutaneous coronary intervention (PCI; commonly known as angioplasty), coronary artery bypass surgery and heart transplantation, increased by 30% between 1996 and 2006 [&lt;ulink linkType="Reference" linkID="1024353"&gt;1024353&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A significant proportion of cardiovascular deaths are attributed to thrombotic events that involve blood platelets [&lt;ulink linkType="Reference" linkID="1024707"&gt;1024707&lt;/ulink&gt;]. In healthy and diseased cardiovascular physiology, platelets have a principal role in hemostasis (the process that serves to prevent bleeding after vascular endothelial disruption characterized by vascular contraction, platelet adhesion and the formation of a soft aggregate plug) [&lt;ulink linkType="Reference" linkID="1024707"&gt;1024707&lt;/ulink&gt;]. Platelet activation in hemostasis involves activator molecules in the subendothelial space of blood vessels, such as the blood glycoprotein (GP) von Willebrand factor, which is the major ligand for the adhesive receptor complex GPIb/V/IX expressed on platelets [&lt;ulink linkType="Reference" linkID="1024707"&gt;1024707&lt;/ulink&gt;]. These interactions lead to the tethering of platelets to the vascular extracellular matrix, where they are further stimulated by various autocrine and paracrine factors including ADP, thromboxane A2 (TXA2), epinephrine and the coagulation protease thrombin [&lt;ulink linkType="Reference" linkID="1024707"&gt;1024707&lt;/ulink&gt;]. The final step in platelet activation involves increased expression and activation of the GPIIb/IIIa receptors, which bind fibrinogen and are involved in the formation of a platelet-fibrin plug (ie, the blood clot or thrombus) over the damaged area [&lt;ulink linkType="Reference" linkID="1024707"&gt;1024707&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Platelet activation, which is central to the pathophysiology of thrombosis, is substantiated by a panel of factors that are commonly associated with hemostasis; thrombin is arguably the most potent of these factors (as assessed by common platelet function testing) [&lt;ulink linkType="Reference" linkID="1024710"&gt;1024710&lt;/ulink&gt;]. Of the two thrombin receptors expressed on human platelets, protease-activated receptor (PAR)-1 and PAR-4, PAR-1 has the highest affinity for thrombin and is thought to mediate the majority of its effects [&lt;ulink linkType="Reference" linkID="437882"&gt;437882&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1024711"&gt;1024711&lt;/ulink&gt;]. The PARs are G-protein-coupled autoreceptors (ie, capable of intramolecular binding for receptor activation), which carry a hidden ligand that becomes exposed by the thrombin-mediated cleavage of a specific N-terminal extracellular site [&lt;ulink linkType="Reference" linkID="1024710"&gt;1024710&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1024711"&gt;1024711&lt;/ulink&gt;]. Upon activation, the PAR-1 receptors promote signaling of diverse platelet events, including the release of inflammatory and mitogenic mediators from platelet granules, TXA2 generation and the activation of GPIIb/IIIa receptors, culminating in platelet aggregation [&lt;ulink linkType="Reference" linkID="1024711"&gt;1024711&lt;/ulink&gt;]. In addition to platelets, PAR-1 receptors are also expressed on other cardiovascular-related cells such as endothelial cells; thrombin mediates endothelial cell contraction and the resulting increased vascular permeability that encourages the transport of materials and increases the exposure of prothrombotic substances in the subendothelial space [&lt;ulink linkType="Reference" linkID="1024710"&gt;1024710&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1024711"&gt;1024711&lt;/ulink&gt;]. PAR-1 receptor activation also increases the expression of adhesion molecules on endothelial cells (such as ICAM-1, VCAM-1, P-selectin and E-selectin), facilitating the recruitment of leukocytes to the damaged area for immunoprotection [&lt;ulink linkType="Reference" linkID="1024710"&gt;1024710&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Multiple antithrombotic agents are used in the acute and chronic treatment of atherothrombosis. In addition to parenteral GPIIb/IIIa receptor antagonists (eg, &lt;ulink linkType="Drug" linkID="2745"&gt;abciximab&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="3467"&gt;tirofiban&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3359"&gt;eptifibatide&lt;/ulink&gt;) and antithrombin agents (eg, heparin, low-molecular weight heparins and direct thrombin inhibitors such as &lt;ulink linkType="Drug" linkID="51508"&gt;hirudin&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="3285"&gt;bivalirudin&lt;/ulink&gt;), oral antiplatelet therapy with &lt;ulink linkType="Drug" linkID="51800"&gt;aspirin&lt;/ulink&gt; (ie, TXA2 biosynthesis prevented by COX-1 inhibition) and antagonism of the predominant ADP receptor P2Y12 with thienopyridine agents are commonly used approaches [&lt;ulink linkType="Reference" linkID="1024544"&gt;1024544&lt;/ulink&gt;]. In the US, the thienopyridines &lt;ulink linkType="Drug" linkID="44382"&gt;ticlopidine&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt; were the only available P2Y12 antagonists on the market until the recent approval of &lt;ulink linkType="Drug" linkID="19001"&gt;prasugrel&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1024853"&gt;1024853&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1031368"&gt;1031368&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="2836"&gt;Clopidogrel&lt;/ulink&gt; has historically been preferred over &lt;ulink linkType="Drug" linkID="44382"&gt;ticlopidine&lt;/ulink&gt; because of the increased incidence of bone marrow toxicity and blood dyscrasias associated with &lt;ulink linkType="Drug" linkID="44382"&gt;ticlopidine&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1024808"&gt;1024808&lt;/ulink&gt;]. Several large-scale clinical trials have demonstrated the value of combination therapy with &lt;ulink linkType="Drug" linkID="51800"&gt;aspirin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt; in a variety of settings, including during and after PCI, non-ST-segment elevation myocardial infarction (ST-segment elevation according to a diagnostic ECG test), previous myocardial infarction and stroke [&lt;ulink linkType="Reference" linkID="758279"&gt;758279&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="800459"&gt;800459&lt;/ulink&gt;]. However, despite the proven benefit on cardiovascular outcomes of antagonizing the TXA2 and ADP pathways with &lt;ulink linkType="Drug" linkID="51800"&gt;aspirin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt;, a significant number of patients experience nocuous and recurrent bleeding events, which may be caused by the disruption of essential protective hemostatic processes that potentially contribute to an increased bleeding risk [&lt;ulink linkType="Reference" linkID="991548"&gt;991548&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1024714"&gt;1024714&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1024715"&gt;1024715&lt;/ulink&gt;]. Importantly, unlike the function of antithrombin agents, PAR-1 antagonism does not block the procoagulant effects of thrombin (fibrin generation) and therefore has no evident effect on bleeding time or other coagulation parameters [&lt;ulink linkType="Reference" linkID="1000524"&gt;1000524&lt;/ulink&gt;]. Thus, blocking platelet activation via the PAR-1 receptor pathway might be hypothesized to have clinical benefits on the inflammatory and vascular repair processes associated with thrombin: PAR-1 inhibition might achieve both the inhibition of thrombosis and the preservation of hemostasis, particularly for atherosclerotic plaques and restenosis following PCI [&lt;ulink linkType="Reference" linkID="991548"&gt;991548&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1025061"&gt;1025061&lt;/ulink&gt;]. Based on this rationalization, &lt;ulink linkType="Company" linkID="19711"&gt;Schering-Plough Corp&lt;/ulink&gt; is developing SCH-530348, a first-in-class PAR-1 antagonist for the potential prevention and treatment of atherothrombosis. SCH-530348 has been awarded Fast-Track status by the FDA, and was undergoing phase III clinical development at the time of publication [&lt;ulink linkType="Reference" linkID="662596"&gt;662596&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="842433"&gt;842433&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1025061"&gt;1025061&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;PAR-1 antagonists from a pyrroloquinazoline and benzimidazol compound series from &lt;ulink linkType="Company" linkID="19711"&gt;Schering-Plough&lt;/ulink&gt; were previously investigated for potency and to determine pharmacokinetic profiles [&lt;ulink linkType="Reference" linkID="335120"&gt;335120&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="425949"&gt;425949&lt;/ulink&gt;]. These compound series were superseded by SCH-530348, a fourth-generation lead in a series of PAR-1 antagonists based on the natural product himbacine, an alkaloid isolated from the bark of Australian magnolias [&lt;ulink linkType="Reference" linkID="403146"&gt;403146&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="587669"&gt;587669&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="923429"&gt;923429&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="987486"&gt;987486&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1024717"&gt;1024717&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1024828"&gt;1024828&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1024831"&gt;1024831&lt;/ulink&gt;]. Himbacine analogs were initially developed as muscarinic antagonists; however, the discovery of three PAR-1 antagonists with high affinity and activity were later identified from a himbacine-related lead compound [&lt;ulink linkType="Reference" linkID="1027515"&gt;1027515&lt;/ulink&gt;]. Initial studies determined that ent-himbacine absolute stereochemistry was preferable for the tricyclic region of the 3-phenylpyridine analog [&lt;ulink linkType="Reference" linkID="923429"&gt;923429&lt;/ulink&gt;]. Substitution at the 5- or 6-position of the pyridine ring was deemed important for PAR-1 binding [&lt;ulink linkType="Reference" linkID="1024716"&gt;1024716&lt;/ulink&gt;]. Further optimization of the series evaluated the incorporation of heteroatoms at the C(7) position of the tricyclic motif, a position known to undergo in vivo metabolism. Variations at the C(7) position were synthesized by reductive amination of the ketone followed by derivatization of the amine to various groups (amide, urea, sulfonamide and carbamate) [&lt;ulink linkType="Reference" linkID="923429"&gt;923429&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1024717"&gt;1024717&lt;/ulink&gt;]. The two most potent ethyl carbamate derivatives were identified, and one was selected for further development because of its reduced lipophilicity [&lt;ulink linkType="Reference" linkID="923429"&gt;923429&lt;/ulink&gt;]. SCH-530348 was 30-fold more potent than the initial lead compound and performed well in functional studies [&lt;ulink linkType="Reference" linkID="923429"&gt;923429&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;SCH-530348, a pyridinyl vinyl dodecahydro-naphtho[2,3-c]furan-6-yl)-carbamate derivative, was synthesized from (3R,3aS,4S,4aR,8aR,9aR)-4-{(E)-2-[5-(3-fluoro-phenyl)-pyridin-2-yl]-vinyl}-3-methyl-decahydro-naphtho[2,3-c]furan-1,7-dione via reductive amination and conversion to carbamate. The starting pyridinyl ethenyl naphtho[2,3-c]furanone derivative was prepared from 3'-methyl-1'-oxo-spiro[1,3-dioxolane-2,7'-3,3a,4,4a,5,6,8,8a,9,9a-decahydrobenzo[f]isobenzofuran]-4'-carbaldehyde (&lt;ulink linkType="Patent" linkID="IN2731536"&gt;US-06063847&lt;/ulink&gt;) and ethyl [(5-triisopropylsilyloxypyridin-2-yl)methyl]phosphonate using a standard Horner-Wadsworth-Emmons reaction. The resultant vinylpyridine compound was desilylated, protected as a triflate, and arylated with 3-fluorophenylboronic acid in the presence of tetrakis(triphenylphosphine)palladium and potassium carbonate to yield the starting pyridinyl vinyl naphtho[2,3-c]furan-1,7-dione compound. Ammonia gas was bubbled through a solution of dione in a mixture of ethanol and dichloromethane for 5 min, cooled to 0degC and then treated with titanium tetraisopropoxide. After stirring at 0degC for 1 h, titanium tetrachloride was added and the solvent was removed after 45 min at room temperature. The remaining residue was dissolved in methanol, treated with sodium trihydridocyanoborate and stirred overnight at room temperature to produce a diastereomeric mixture (alpha:beta 2:1) of the corresponding 7-amino derivative in 64% yield. The 7alpha-amino was separated and converted to the ethyl carbamate derivative (SCH-530348) in 79% yield using ethyl chloroformate and triethylamine [&lt;ulink linkType="Reference" linkID="923429"&gt;923429&lt;/ulink&gt;]. Several similar processes for the synthesis of SCH-530348 have been published [&lt;ulink linkType="Reference" linkID="1024828"&gt;1024828&lt;/ulink&gt;], (&lt;ulink linkType="Patent" linkID="PA2877271"&gt;WO-03089428&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA3215236"&gt;WO-2006076564&lt;/ulink&gt;), and the syntheses of various intermediates has also been described (&lt;ulink linkType="Patent" linkID="PA3215284"&gt;WO-2006076415&lt;/ulink&gt;, &lt;ulink linkType="Patent" linkID="PA3215268"&gt;WO-2006076452&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA3215235"&gt;WO-2006076565&lt;/ulink&gt;).&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Preclinical development&lt;/subtitle&gt;Preclinical development of SCH-530348 was performed using the platelets of humans or non-human primates, because PAR-1 expression is lacking on the platelets of mice, rats, rabbits and dogs [&lt;ulink linkType="Reference" linkID="1000524"&gt;1000524&lt;/ulink&gt;]. In in vitro binding studies using high-affinity [3H]TRAP (thrombin receptor-activating peptide; 10 nM) as a ligand, SCH-530348 competitively antagonized human platelet membrane-derived PAR-1 with a Ki value of 8.1 nM [&lt;ulink linkType="Reference" linkID="923429"&gt;923429&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="957538"&gt;957538&lt;/ulink&gt;]. The competitive binding profile of SCH-530348 for the PAR-1 receptor was confirmed with Scatchard plots of saturation binding and kinetic studies that demonstrated a dissociation half-life from the receptor of approximately 20 h [&lt;ulink linkType="Reference" linkID="923429"&gt;923429&lt;/ulink&gt;]. SCH-530348 was inactive in PAR-2 and PAR-3 binding and PAR-4 functional assays, and was selective for PAR-1 over other tested GPCRs, ion channels and receptors (no data available) [&lt;ulink linkType="Reference" linkID="923429"&gt;923429&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="957538"&gt;957538&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In human coronary artery smooth muscle cells, SCH-530348 inhibited thrombin-stimulated calcium mobilization and blocked thrombin-stimulated [3H]thymidine incorporation with Ki values of 1.1 and 13 nM, respectively [&lt;ulink linkType="Reference" linkID="923429"&gt;923429&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="957538"&gt;957538&lt;/ulink&gt;]. In human platelet-rich plasma, SCH-530348 inhibited thrombin- and high-affinity TRAP-induced platelet aggregation with IC50 values of 47 and 25 nM, respectively; in contrast, the compound exhibited no effect on platelet aggregation induced by collagen, ADP, a standard thromboxane mimetic and a PAR-4 agonist peptide [&lt;ulink linkType="Reference" linkID="923429"&gt;923429&lt;/ulink&gt;]. In ex vivo whole-blood samples obtained from cynomolgus monkeys after dosing &gt;/= 1 mg/kg (po), SCH-530348 potently inhibited TRAP-induced platelet aggregation for at least 24 h [&lt;ulink linkType="Reference" linkID="923429"&gt;923429&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="957538"&gt;957538&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;An in vivo study in cynomolgus monkeys investigated whether SCH-530348 could be added to the standard-of-care treatment for atherothrombosis without incurring an additional bleeding risk [&lt;ulink linkType="Reference" linkID="914215"&gt;914215&lt;/ulink&gt;]. Anesthetized monkeys were dosed with SCH-530348 (1 mg/kg) alone or in addition to &lt;ulink linkType="Drug" linkID="51800"&gt;aspirin&lt;/ulink&gt; (10 mg/kg) plus &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt; (2 mg/kg), and bleeding risk was assessed 2 h after dosing [&lt;ulink linkType="Reference" linkID="914215"&gt;914215&lt;/ulink&gt;]. The administration of &lt;ulink linkType="Drug" linkID="51800"&gt;aspirin&lt;/ulink&gt; plus &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt; (mean template bleeding time = 23.2 min; mean surgical blood loss = 2.0 ml/h) was associated with a significant (p &amp;lt; 0.05) increase in bleeding risk compared with vehicle (3.4 min; 0.13 ml/h). In contrast, SCH-530348 did not appear to increase bleeding risk when administered alone (4.9 min; 0.18 ml/h), or to exacerbate bleeding risk when administered in combination with &lt;ulink linkType="Drug" linkID="51800"&gt;aspirin&lt;/ulink&gt; plus &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt; (21.9 min; 2.03 ml/h) [&lt;ulink linkType="Reference" linkID="914215"&gt;914215&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;In preclinical studies, toxicities to SCH-530348 were species-specific and identified at doses 3- to 300-fold in excess of the exposure of the recommended therapeutic dose in humans [&lt;ulink linkType="Reference" linkID="785446"&gt;785446&lt;/ulink&gt;]. Toxic symptoms manifested by rats included reversible phospholipidosis, retinal vacuolation, hepatic thrombi, skeletal muscle degeneration and lymphoid necrosis. Sertoli cell vacuolation, phospholipidosis and alterations to the histopathology of the urinary bladder, ureter, epididymis and kidneys were observed in mice. Monkeys exhibited transient acute inflammatory changes, swollen lymph nodes, Kupffer cell hyperplasia, tremors/convulsions and phospholipidosis [&lt;ulink linkType="Reference" linkID="785446"&gt;785446&lt;/ulink&gt;]. Importantly, SCH-530348 demonstrated no effects on clotting parameters such as prothrombin time and activated partial thromboplastin time [&lt;ulink linkType="Reference" linkID="923429"&gt;923429&lt;/ulink&gt;]. In addition, no metabolism and mechanism-based inhibition of cytochrome p450 isozymes (including CYP1A2, CYP2C9, CYP2C19, CYP2D16 or CYP3A4) were observed in human liver microsomes at high concentrations of SCH-530348 (90 microM) [&lt;ulink linkType="Reference" linkID="923429"&gt;923429&lt;/ulink&gt;]. This finding was confirmed in rats, in which SCH-530348 demonstrated a 'clean profile' in an 8-day enzyme induction study [&lt;ulink linkType="Reference" linkID="923429"&gt;923429&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism and pharmacokinetics&lt;/subtitle&gt;In rats, SCH-530348 (10 mg/kg po) was 68% absorbed, and had a bioavailability of 33%, an AUC0-24 h value of 5.3 microM.h, a Cmax value of 0.67 microM and a Tmax value of 3 h [&lt;ulink linkType="Reference" linkID="923429"&gt;923429&lt;/ulink&gt;]. In monkeys, SCH-530348 (1 mg/kg po) was 82% absorbed, with a bioavailability of 86%, AUC0-24 h of 10 microM.h, Cmax of 1.3 microM and Tmax of 1 h. At 0.1 mg/kg, the AUC0-24 h and Cmax values for SCH-530348 were 0.20 microM.h and 0.018 microM, respectively, following oral dosing in monkeys, indicating a dose-dependent effect of the compound. The elimination t1/2 values of SCH-530348 in rats (10 mg/kg iv) and monkeys (1.0 mg/kg iv) were 5.1 and 13 h, respectively [&lt;ulink linkType="Reference" linkID="923429"&gt;923429&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In phase I/II clinical trials of SCH-530348, rapid distribution and slow elimination were observed for all dosing regimens (up to 40 mg po or up to 2.5 mg/day po). The terminal t1/2 value in humans ranged from 126 to 311 h; exposure to SCH-530348 was dose-related, with an interindividual variability of 20 to 40% [&lt;ulink linkType="Reference" linkID="1025061"&gt;1025061&lt;/ulink&gt;]; and steady-state was achieved within 21 days [&lt;ulink linkType="Reference" linkID="633128"&gt;633128&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="850762"&gt;850762&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1000522"&gt;1000522&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1022099"&gt;1022099&lt;/ulink&gt;]. SCH-530348 was metabolized by oxidation, primarily by CYP3A4, and was eliminated by the gastrointestinal and biliary systems; the feces were the predominant route of elimination, and renal clearance accounted for &amp;lt; 5% of the total dose [&lt;ulink linkType="Reference" linkID="991548"&gt;991548&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1025061"&gt;1025061&lt;/ulink&gt;]. The action of CYP3A4 in the metabolism of SCH-530348 was confirmed in coadministration studies in which the CYP3A4 inhibitor &lt;ulink linkType="Drug" linkID="44299"&gt;ketoconazole&lt;/ulink&gt; increased exposure by 2-fold, while the CYP3A4 inducer rifampin decreased exposure by 50%, after 3 weeks [&lt;ulink linkType="Reference" linkID="1025061"&gt;1025061&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase I, randomized, open-label, single-dose, parallel-group clinical trial assessed the pharmacokinetics of SCH-530348 (40 mg/kg po) in healthy volunteers (n = 83) [&lt;ulink linkType="Reference" linkID="1000523"&gt;1000523&lt;/ulink&gt;]. Food intake moderately delayed the absorption of the compound; the median Tmax value for fasted (10 h) volunteers was 1 h, compared with 3 h when SCH-530348 was administered 5 min after food intake and 2 h when administered 1 or 2 h after food intake. Administration of SCH-530348 5 min after food intake increased mean Cmax and AUC values by 31 and 43%, respectively, compared with administration in fasted volunteers [&lt;ulink linkType="Reference" linkID="1000523"&gt;1000523&lt;/ulink&gt;]. Coadministration of antacids with SCH-530348 in fasted volunteers (SCH-530348 administered 5 min after antacid) modestly delayed absorption of the drug (median Tmax = 2 h) and decreased Cmax and AUC values by 38 and 15%, respectively, compared with SCH-530348 administered alone. Thus, SCH-530348 could be administered effectively with or without food or antacids [&lt;ulink linkType="Reference" linkID="1000523"&gt;1000523&lt;/ulink&gt;]. In addition, no significant differences in pharmacokinetics were observed between healthy Caucasian and Japanese volunteers or between males and females [&lt;ulink linkType="Reference" linkID="1000522"&gt;1000522&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1025061"&gt;1025061&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical development&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;A phase I, randomized, evaluator-blind, placebo-controlled, ascending-dose, parallel-group clinical &lt;ulink linkType="Protocol" linkID="5056"&gt;trial&lt;/ulink&gt; evaluated single doses of SCH-530348 (0.25 to 40 mg po) in healthy volunteers (n = 50) [&lt;ulink linkType="Reference" linkID="633128"&gt;633128&lt;/ulink&gt;]. SCH-530348 potently and dose-dependently inhibited TRAP-induced (15 microM) platelet aggregation compared with placebo. Maximal effects (&gt; 90% inhibition of platelet aggregation) were achieved as early as 1 h post-administration with doses of 20 or 40 mg [&lt;ulink linkType="Reference" linkID="633128"&gt;633128&lt;/ulink&gt;]. Consistent inhibition (&gt; 80%) was present at 1 h post-administration only with the 40-mg dose, although the majority of volunteers on the 20-mg dose achieved this benchmark at 2 h [&lt;ulink linkType="Reference" linkID="1025061"&gt;1025061&lt;/ulink&gt;]. The effects of SCH-530348 were long-lasting, with &amp;gt; 90% inhibition maintained for at least 72 h in all doses &gt;/= 5 mg [&lt;ulink linkType="Reference" linkID="633128"&gt;633128&lt;/ulink&gt;]. The recovery of platelet function was slow and dose-dependent; 50% of the baseline platelet function had returned by 1, 2 and 3 weeks post-administration of 10-, 20- and 40-mg doses of SCH-530348, respectively [&lt;ulink linkType="Reference" linkID="1025061"&gt;1025061&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In parallel to the previously described clinical trial, a phase I, randomized, evaluator-blind, placebo-controlled, ascending-dose trial assessed multiple doses of SCH-530348 (1, 3 and 5 mg/day po for 28 days) in healthy volunteers (n = 36) [&lt;ulink linkType="Reference" linkID="1000521"&gt;1000521&lt;/ulink&gt;]. SCH-530348 induced &amp;gt; 80% inhibition of TRAP-induced (15 microM) platelet aggregation after 1 day of treatment with the 5-mg dose and by 7 days of treatment with the 1- or 3-mg dose. A subset of volunteers (n = 12) received a single, oral loading dose of 10 or 20 mg of SCH-530348 followed by a 1-mg/day dose for 6 days (the maintenance dose). With the maintenance dose and either loading regimen, 80% inhibition of platelet aggregation was obtained within 1 to 2 h, and was maintained through day 7; platelet function recovery to 50% of baseline varied from several weeks to &amp;gt; 2 months [&lt;ulink linkType="Reference" linkID="1000521"&gt;1000521&lt;/ulink&gt;]. The results indicated that the 1-mg dose of SCH-530348 would be adequate to provide maintenance therapy, whereas for a rapid onset of action, such as in acute coronary syndrome, a loading dose would be necessary [&lt;ulink linkType="Reference" linkID="1000521"&gt;1000521&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;To identify the optimized dosing regimen of SCH-530348, a phase I, randomized, evaluator-blind, placebo-controlled, ascending-dose, parallel-group clinical trial evaluated the pharmacodynamics and pharmacokinetics of multiple dosing regimens (5, 10, 20 or 40 mg po as a single loading dose or 0.5, 1.0 or 2.5 mg/day po as a maintenance dose for 28 days) in healthy volunteers (n = 111) [&lt;ulink linkType="Reference" linkID="1022099"&gt;1022099&lt;/ulink&gt;]. Of the three doses administered daily, only the 2.5-mg dose of SCH-530348 consistently inhibited TRAP-induced (15 microM) platelet aggregation by &amp;gt; 80% over 28 days [&lt;ulink linkType="Reference" linkID="1022099"&gt;1022099&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1025061"&gt;1025061&lt;/ulink&gt;]. Of the loading doses, 40 mg of SCH-530348 was most potent after 1 h, indicating that the application of a 40-mg loading dose and a 2.5-mg maintenance dose would provide the most consistent inhibition of TRAP-induced aggregation at the target level for the entire 28-day study period [&lt;ulink linkType="Reference" linkID="1022099"&gt;1022099&lt;/ulink&gt;]. Similar results were obtained from a phase I, randomized, open-label clinical trial with a replica dosing protocol in healthy Japanese and Caucasian volunteers (n = 98) [&lt;ulink linkType="Reference" linkID="1000522"&gt;1000522&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;A phase II, multicenter, randomized, double-blind, placebo-controlled clinical trial (ClinicalTrials.gov identifier: &lt;ulink linkType="Protocol" linkID="4538"&gt;NCT00132912&lt;/ulink&gt;; P03573AM1; P03573), known as the Thrombin Receptor Antagonist in PCI (TRA-PCI) trial, evaluated the tolerability and safety of SCH-530348 in patients (n = 1030) with symptoms of coronary artery disease who were scheduled to undergo non-urgent PCI. In the primary cohort, patients were randomized to receive a 10-, 20- or 40-mg oral loading dose of SCH-530348 or placebo. Patients who underwent PCI successfully (the PCI cohort) were further randomized to a daily maintenance dose of SCH-530348 (0.5, 1 or 2.5 mg/day po) plus standard of care (&lt;ulink linkType="Drug" linkID="51800"&gt;aspirin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt;) for those who had received an SCH-530348 loading dose, or were randomized to placebo plus standard of care for those who had received a placebo loading dose. Patients who did not undergo PCI did not receive any further investigational treatment beyond the loading dose. Of the 1030 patients recruited, 573 underwent PCI and 460 completed the loading and maintenance dose treatments until day 60 [&lt;ulink linkType="Reference" linkID="850762"&gt;850762&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="991548"&gt;991548&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="991379"&gt;991379&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1000650"&gt;1000650&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1025061"&gt;1025061&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Although the TRA-PCI trial was not powered for efficacy, the primary cohort was associated with a reduction in the occurrence of death or myocardial infarction compared with the placebo group (4.3% of patients administered SCH-530348 versus 7.3% for placebo); this effect appeared to be dose-related (5.4, 4.2 and 3.5% for doses of 10, 20 and 40 mg, respectively). In the PCI cohort, the incidence of death or major adverse cardiac events at 60 days was similar between patients receiving placebo (9%) and SCH-530348 (6% combined for all doses; a 33% reduction). At the highest overall dose (40 mg plus 2.5 mg/day), the incidence of death or major adverse cardiac events at 60 days was 7%. The reduction in major adverse cardiac events occurred predominantly because of a reduced incidence of myocardial infarction (7% with placebo versus 4% with SCH-530348 [43% reduction]). At the highest total dose of SCH-530348, cardiovascular events alone were reduced by 48%; however, this finding was not statistically significant from placebo. SCH-530348 was not associated with a significant increase in the rate of major or minor TIMI (thrombolysis in myocardial infarction) bleeding compared with placebo (1.6, 2.5 and 4.0% of patients in the 10-, 20- and 40-mg loading dose groups, respectively, and 2.2, 3.6 and 2.9% of patients in the 0.5-, 1.0- and 2.5-mg maintenance dose groups, respectively, compared with 3.3% for placebo) [&lt;ulink linkType="Reference" linkID="991548"&gt;991548&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1000524"&gt;1000524&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1025061"&gt;1025061&lt;/ulink&gt;]. At 2 h post-administration, &gt;/= 80% inhibition of TRAP-induced platelet aggregation was achieved in 42.9, 52.9 and 96.3% of patients receiving the 10-, 20- and 40-mg loading doses of SCH-530348, respectively. The effect of the maintenance dose appeared to be more efficient than in phase I trials, with &gt;/= 80% platelet aggregation inhibition observed in 90, 100 and 100% of patients receiving 0.5, 1 or 2.5 mg of SCH-530348, respectively, at 30 and 60 days, compared with 9 and 11% at 30 and 60 days for patients receiving placebo [&lt;ulink linkType="Reference" linkID="850762"&gt;850762&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1025061"&gt;1025061&lt;/ulink&gt;]. A phase II, randomized, double-blind, placebo-controlled, parallel-assignment clinical trial (&lt;ulink linkType="Protocol" linkID="15614"&gt;NCT00684203&lt;/ulink&gt;; P04772) evaluated the safety and efficacy of SCH-530348 (20 or 40 mg po loading dose on day 1, and 1 or 2.5 mg/day po maintenance dose from day 2 to 60) in Japanese patients with acute coronary syndromes (n = 117) receiving standard-of-care treatment (ie, &lt;ulink linkType="Drug" linkID="51800"&gt;aspirin&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="44382"&gt;ticlopidine&lt;/ulink&gt; and heparin); 79% of these patients underwent PCI [&lt;ulink linkType="Reference" linkID="1022101"&gt;1022101&lt;/ulink&gt;]. In the PCI cohort, treatment with SCH-530348 caused a statistically significant reduction in periprocedural myocardial infarction (15.0 and 19.4% at doses of 20 and 40 mg, respectively, and 16.9% overall for all doses) compared with placebo (42.9%) [&lt;ulink linkType="Reference" linkID="1022101"&gt;1022101&lt;/ulink&gt;]. The addition of SCH-530348 to standard-of-care therapy did not significantly increase TIMI major (3 versus 0% with SCH-530348 and placebo, respectively) or minor bleeding (11 versus 10%). A limited number of patients were randomized to receive placebo in the non-PCI cohort, preventing the calculation of meaningful efficacy data [&lt;ulink linkType="Reference" linkID="1022101"&gt;1022101&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase II, randomized, double-blind, placebo-controlled, parallel-assignment clinical trial (&lt;ulink linkType="Protocol" linkID="15605"&gt;NCT00684515&lt;/ulink&gt;; P05005AM5; P05005) evaluated the effect of SCH-530348 (1 or 2.5 mg/day po for 60 days) in Japanese patients with atherothrombosis and prior ischemic stroke (n = 93) who were receiving standard-of-care therapy (&lt;ulink linkType="Drug" linkID="51800"&gt;aspirin&lt;/ulink&gt;) [&lt;ulink linkType="Reference" linkID="1022100"&gt;1022100&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1026945"&gt;1026945&lt;/ulink&gt;]. In data collated from 90 patients, SCH-530348 in addition to standard-of-care antiplatelet therapy induced no increase in the rate of major or minor TIMI bleeding compared with placebo [&lt;ulink linkType="Reference" linkID="1022100"&gt;1022100&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1026945"&gt;1026945&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;At the time of publication, several phase III clinical trials were ongoing. A phase III, randomized, double-blind, placebo-controlled, parallel-assignment, prevention clinical trial (&lt;ulink linkType="Protocol" linkID="4439"&gt;NCT00527943&lt;/ulink&gt;; P04736AM1; P04736), known as the TRA-CER trial, was recruiting patients (expected n = 10,000) with acute coronary syndromes to assess the safety and efficacy of SCH-530348 (40 mg po loading dose administered 1 h before surgical intervention on day 1, followed by a maintenance dose [2.5 mg/day po] from day 2 for at least 1 year) versus standard of care in preventing myocardial infarction and stroke [&lt;ulink linkType="Reference" linkID="1025061"&gt;1025061&lt;/ulink&gt;]. The primary efficacy endpoint was the first occurrence of any component of the composite of cardiovascular death, myocardial infarction, stroke, recurrent ischemia with rehospitalization and urgent coronary revascularization. The secondary endpoint was the first occurrence of any component of the composite of cardiovascular death, myocardial infarction or stroke [&lt;ulink linkType="Reference" linkID="1025061"&gt;1025061&lt;/ulink&gt;]. Completion of the trial was expected in July 2011.&lt;/para&gt;&lt;para&gt;A phase III, prevention, randomized, double-blind, placebo-controlled, parallel-assignment clinical trial (&lt;ulink linkType="Protocol" linkID="4441"&gt;NCT00526474&lt;/ulink&gt;; P04737; TRA 2P - TIMI 50) was recruiting patients (expected n = 25,000) with a known history of atherosclerosis to assess the safety and efficacy of SCH-530348 (2.5 mg/day po for at least 1 year) versus standard of care in preventing heart attack and stroke. The primary efficacy endpoint was the first occurrence of any component of the composite of cardiovascular death, myocardial infarction, stroke or urgent coronary revascularization. The first occurrence of any component of the composite of cardiovascular death, myocardial infarction and stroke were the three components of the secondary endpoint. Completion of the trial was expected in September 2010.&lt;/para&gt;&lt;para&gt;A phase III, prevention, randomized, double-blind, placebo-controlled, parallel-assignment clinical trial (&lt;ulink linkType="Protocol" linkID="56782"&gt;NCT00617123&lt;/ulink&gt;; P05183) was recruiting patients (n = 200) with established atherosclerotic disease who were already enrolled in the TRA 2P - TIMI 50 study to evaluate the ocular safety of SCH-530348 (2.5 mg/day po for at least 1 year). The primary and secondary outcome measures were the incidence of vacuolization in the inner nuclear layer of the retina and decreased visual acuity score of at least seven letters from baseline, respectively. Completion of the trial was expected in September 2010.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side effects and contraindications&lt;/subtitle&gt;In phase I clinical trials conducted in healthy volunteers, SCH-530348 was reported to be well tolerated. Adverse events were mild, non-specific and similar among treatment groups (0.5- to 40-mg doses of SCH-530348, and placebo) [&lt;ulink linkType="Reference" linkID="633128"&gt;633128&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1000521"&gt;1000521&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1000522"&gt;1000522&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1022099"&gt;1022099&lt;/ulink&gt;]. The most common adverse events were upper respiratory tract infection, headache and fatigue. No significant abnormalities or changes in clinical laboratory tests, including liver function tests, coagulation, bleeding time, vital signs or ECGs, were identified [&lt;ulink linkType="Reference" linkID="633128"&gt;633128&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1000522"&gt;1000522&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1022099"&gt;1022099&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the phase II, TRA-PCI clinical trial, SCH-530348 was also reported to be well tolerated. The most common adverse events to cause trial discontinuation included non-TIMI bleeding and non-specific gastrointestinal symptoms such as nausea [&lt;ulink linkType="Reference" linkID="991548"&gt;991548&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1000650"&gt;1000650&lt;/ulink&gt;]. The frequency of adverse events was similar across treatment groups; for patients who underwent PCI, discontinuations as a consequence of non-TIMI bleeding and gastrointestinal symptoms did not differ significantly between placebo (4%) and SCH-530348 (6%) [&lt;ulink linkType="Reference" linkID="991548"&gt;991548&lt;/ulink&gt;]. All bleeding events were increased in a dose-dependent manner for both the loading and maintenance regimens. A statistically significant difference in bleeding between the highest dose of SCH-530348 (40 mg plus 2.5 mg) versus placebo was identified (50% versus 32%, respectively); this finding was predominantly associated with non-TIMI bleeds [&lt;ulink linkType="Reference" linkID="991548"&gt;991548&lt;/ulink&gt;]. Furthermore, there was no difference in the rate of discontinuations because of non-TIMI bleeding between SCH-530348 (1%) and placebo (1%). Arterial access site, skin and mucous membranes were the most common locations for bleeding [&lt;ulink linkType="Reference" linkID="991548"&gt;991548&lt;/ulink&gt;]. Most patients who underwent coronary artery bypass grafting demonstrated TIMI major or minor bleeding; in these patients, volume loss (as assessed by chest-tube drainage) was similar in the SCH-530348 and placebo groups [&lt;ulink linkType="Reference" linkID="1025061"&gt;1025061&lt;/ulink&gt;]. An increase in TIMI major bleeding occurred more frequently in SCH-530348-treated patients (63%) versus those receiving placebo (38%), although this effect was not dose-dependent [&lt;ulink linkType="Reference" linkID="991548"&gt;991548&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the Japanese patients with acute coronary syndromes undergoing PCI in a phase II clinical trial, bleeding events were similar between placebo- (52%) and SCH-530348-treated (61%) groups [&lt;ulink linkType="Reference" linkID="1022101"&gt;1022101&lt;/ulink&gt;]. The addition of SCH-530348 to standard-of-care therapy did not significantly increase non-TIMI bleeding (55%) versus placebo (52%). In addition, the incidence of trial discontinuations because of adverse events and serious adverse events was similar in SCH-530348 (20 and 8%, respectively) and placebo groups (38 and 14%, respectively) [&lt;ulink linkType="Reference" linkID="1022101"&gt;1022101&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Patent summary&lt;/subtitle&gt;SCH-530348 is covered by &lt;ulink linkType="Company" linkID="19711"&gt;Schering-Plough&lt;/ulink&gt;'s &lt;ulink linkType="Patent" linkID="PA2877271"&gt;WO-03089428&lt;/ulink&gt;, which was granted in the US as &lt;ulink linkType="Patent" linkID="PA3174631"&gt;US-07304078&lt;/ulink&gt; with an expiry extension under US154 until April 2024. &lt;ulink linkType="Company" linkID="19711"&gt;Schering-Plough&lt;/ulink&gt; claims processes for the synthesis of SCH-530348 in four patent applications, &lt;ulink linkType="Patent" linkID="PA3215284"&gt;WO-2006076415&lt;/ulink&gt;, &lt;ulink linkType="Patent" linkID="PA3215268"&gt;WO-2006076452&lt;/ulink&gt;, &lt;ulink linkType="Patent" linkID="PA3215236"&gt;WO-2006076564&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA3590168"&gt;WO-2008005348&lt;/ulink&gt;. &lt;ulink linkType="Patent" linkID="PA3215236"&gt;WO-2006076564&lt;/ulink&gt; was granted in the US as &lt;ulink linkType="Patent" linkID="PA3220657"&gt;US-07541471&lt;/ulink&gt;, with an extension under US154 that is due to expire in March 2027. &lt;ulink linkType="Company" linkID="19711"&gt;Schering-Plough&lt;/ulink&gt; has additional claims on novel formulations of SCH-530348, including oral capsule and immediate-release tablet formulations (&lt;ulink linkType="Patent" linkID="PA3590073"&gt;WO-2008005352&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA3589729"&gt;WO-2008005353&lt;/ulink&gt;) and rapidly disintegrating solid-dosage forms (&lt;ulink linkType="Patent" linkID="PA3621483"&gt;WO-2008039406&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA3655932"&gt;WO-2008079260&lt;/ulink&gt;). &lt;ulink linkType="Company" linkID="19711"&gt;Schering-Plough&lt;/ulink&gt; claims the use of SCH-530348 for treating various disorders, including for the treatment of cardiovascular, inflammatory, respiratory tract or neurodegenerative diseases and cancer (&lt;ulink linkType="Patent" linkID="PA2988386"&gt;WO-2005046688&lt;/ulink&gt;, &lt;ulink linkType="Patent" linkID="PA3518331"&gt;WO-2007075964&lt;/ulink&gt;, &lt;ulink linkType="Patent" linkID="PA3518874"&gt;WO-2007075808&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA3600385"&gt;WO-2008016378&lt;/ulink&gt;). &lt;ulink linkType="Patent" linkID="PA2988386"&gt;WO-2005046688&lt;/ulink&gt;, covering crystalline forms of a bisulfate salt of SCH-530348, was granted in the US as &lt;ulink linkType="Patent" linkID="PA2961241"&gt;US-07235567&lt;/ulink&gt; with an expiry of June 2021.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current opinion&lt;/subtitle&gt;By targeting the PAR-1 receptor, SCH-530348 possesses a novel mechanism of action. Unlike with antithrombin agents, a decreased bleeding liability might be possible with a PAR-1 receptor antagonist because the coagulation activities of thrombin (ie, generation of fibrin) remain intact. However, SCH-530348 surprisingly does not possess similar bleeding effects to &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt;, as both antagonists block receptor coupling to platelet stimulatory G-proteins and mediate similar platelet activation events (particularly given that ex vivo thrombin is arguably a more potent agonist than ADP). Nonetheless, a lack of increased bleeding with SCH-530348 has been reported consistently in several animal models and preliminary clinical trials. Based on animal studies, investigators have proposed that the PAR-1 receptor is not essential for hemostasis, and therefore inhibition of this pathway may not increase bleeding risk noticeably [&lt;ulink linkType="Reference" linkID="1000524"&gt;1000524&lt;/ulink&gt;]. Ex vivo studies demonstrated that SCH-530348 did not inhibit collagen, ADP or arachidonic acid-stimulated platelet aggregation [&lt;ulink linkType="Reference" linkID="923429"&gt;923429&lt;/ulink&gt;]. Furthermore, the apparently redundant PAR-4 receptor on human platelets may serve as a rescue mechanism for the healthy response, as the receptor requires higher thrombin concentrations for activation [&lt;ulink linkType="Reference" linkID="437882"&gt;437882&lt;/ulink&gt;]. Regardless of the mechanism, if nonexistent or even trivial bleeding is confirmed in phase III clinical trials with preserved efficacy benefits, SCH-530348 could assume a prominent role in the prevention of adverse cardiovascular events as additive therapy and potentially even as replacement therapy for other antiplatelet agents in the long term, if appropriate head-to-head studies are conducted. The more-established field of ADP receptor antagonism at the P2Y12 receptor has been useful in determining that bleeding risk and efficacy are difficult to balance at the population level, and that ex vivo platelet function testing is not necessarily the best predictor of clinical efficacy as demonstrated by the recent failure of &lt;ulink linkType="Drug" linkID="19901"&gt;cangrelor&lt;/ulink&gt;, a P2Y12 receptor antagonist [&lt;ulink linkType="Reference" linkID="1009117"&gt;1009117&lt;/ulink&gt;]. Novel strategies for evaluating platelet function are emerging, but a feasible, consistent and clinically meaningful assay with a proven target level of inhibition has yet to be established [&lt;ulink linkType="Reference" linkID="1024718"&gt;1024718&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Because the PAR-1 receptor is not isolated to platelets, other thrombin-mediated effects on inflammation and other processes may be critical for the clinical development of SCH-530348. Additional effects of PAR-1 receptor antagonism on inflammation and vascular repair appear promising [&lt;ulink linkType="Reference" linkID="1024710"&gt;1024710&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1024711"&gt;1024711&lt;/ulink&gt;], particularly in the setting of PCI; however, the clinical impact of these effects is not well studied and, like the effects on platelet activation, requires confirmation from large-scale clinical trials. Thus, a multitude of questions remain to be answered regarding the pharmacological effects of PAR-1 receptor antagonism.&lt;/para&gt;&lt;para&gt;In addition to its complicated receptor target (SCH-530348 antagonizes irreversible thrombin-mediated cleavage of an intramolecular tethered ligand), SCH-530348 also possesses some notable pharmacokinetic features. The compound is technically reversible, although it dissociates from the receptor slowly, such that its pharmacodynamic effect appears irreversible (typical t1/2 &amp;gt; 1 week). The potential importance of these characteristics is essentially unknown. Although SCH-530348 slowly dissociates, it is not clear whether thrombin receptor antagonism may have a rebound platelet effect when the tethered ligand is again exposed; furthermore, any possible effects of SCH-530348 on PAR-1 receptor internalization have not been defined. The metabolism of SCH-530348 occurs by CYP3A4; the potent induction or inhibition of CYP3A4 invokes extreme changes in SCH-530348 levels, although the therapeutic window for PAR-1 receptor antagonism has not been well established. Nonetheless, these metabolic effects appear to be reasonably predictable and manageable from a pharmacotherapy perspective.&lt;/para&gt;&lt;para&gt;One potentially concerning aspect of the phase III TRA-CER clinical trial is the selection of the highest loading and maintenance doses of SCH-530348. In the phase II TRA-PCI trial in patients undergoing PCI, lower maintenance doses yieled more favorable results than the 2.5-mg dose on clinical efficacy (death and major adverse cardiac events), as demonstrated by a lower event rate in the 40-mg loading dose group with all maintenance doses compared with the 40-mg loading dose plus 2.5 mg maintenance dose. The specific results for all other loading/maintenance dose combinations had not been presented in the data available at the time of publication. In addition to the issue of maintenance dose selected, a similar concern was identified for the loading dose selected. Although increasing the loading dose from 20 to 40 mg resulted in a dose-dependent efficacy benefit (ie, 5.4 versus 4.2% event rate, respectively), the change in dose was also associated with an incremental increase in major or minor TIMI bleeding (ie, 2.5 versus 4.0% bleeding rate, respectively). Interestingly, these dose-dependent findings for the loading dose were not apparent in the phase II trial in Japanese patients. Nonetheless, the loading dose selected appears to have been based upon the faster onset and more potent inhibition of platelet aggregation observed in ex vivo platelet studies. The higher loading dose also inhibited TRAP-induced platelet function to a greater extent and more uniformly in patients; such inhibition could be a critical feature for efficacy. However, no evidence exists to recommend a target level of inhibition by ex vivo testing for any agonist or antiplatelet agent. In the preliminary phase II results, the added clinical efficacy of the higher dose of SCH-530348 was also associated with an increased occurrence of bleeding events.&lt;/para&gt;&lt;para&gt;Finally, the most important factor to solidify the success of SCH-530348 (if the compound is deemed to be safe and effective in phase III clinical trials) is likely to be the pharmacological landscape at the time of the expected filing of the drug in 2010 or 2011 [&lt;ulink linkType="Reference" linkID="966270"&gt;966270&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="2836"&gt;Clopidogrel&lt;/ulink&gt; has established and maintained the dominant position in the marketplace alongside standard-of-care platelet inhibition with &lt;ulink linkType="Drug" linkID="51800"&gt;aspirin&lt;/ulink&gt;. Although &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt; has validated clinical benefit and widespread use, the drug has important limitations associated with its use. Like all thienopyridines, &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt; requires hepatic conversion by the CYP system to its active metabolite, and binds irreversibly to the P2Y12 receptor for the life of the platelet [&lt;ulink linkType="Reference" linkID="1024720"&gt;1024720&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1024721"&gt;1024721&lt;/ulink&gt;]. In addition, extensive variability in response to &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt; has been observed with ex vivo platelet function testing, 4 to 30% of patients are estimated not to achieve the expected level of inhibition (depending on the definition of responsiveness and assay employed) [&lt;ulink linkType="Reference" linkID="1024722"&gt;1024722&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1024723"&gt;1024723&lt;/ulink&gt;]. Given these limitations with &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt;, several new antiplatelet agents have been progressed to advanced stages of development. &lt;ulink linkType="Drug" linkID="19001"&gt;Prasugrel&lt;/ulink&gt;, a third-generation thienopyridine, has been approved in several countries including the US. Compared with &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="19001"&gt;prasugrel&lt;/ulink&gt; possesses more consistent metabolism to its active metabolite, reduced variability and increased efficacy, but with resultant increased bleeding [&lt;ulink linkType="Reference" linkID="859496"&gt;859496&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1029822"&gt;1029822&lt;/ulink&gt;]. However, the inherent disadvantages of the thienopyridines (ie, inactive prodrug and irreversibility) remain. Non-thienopyridine compounds in development include several agents that antagonize the target of &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt; (ie, the P2Y12 receptor), such as the phase III clinical candidate &lt;ulink linkType="Drug" linkID="36332"&gt;ticagrelor&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="14190"&gt;AstraZeneca plc&lt;/ulink&gt;) [&lt;ulink linkType="Reference" linkID="1008341"&gt;1008341&lt;/ulink&gt;] and elinogrel (&lt;ulink linkType="Company" linkID="1005894"&gt;Portola Pharmaceuticals Inc&lt;/ulink&gt;/&lt;ulink linkType="Company" linkID="23137"&gt;Novartis AG&lt;/ulink&gt;) in phase II clinical development [&lt;ulink linkType="Reference" linkID="983503"&gt;983503&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;With multiple agents in development, &lt;ulink linkType="Drug" linkID="51800"&gt;aspirin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt;/&lt;ulink linkType="Drug" linkID="44382"&gt;ticlopidine&lt;/ulink&gt;/&lt;ulink linkType="Drug" linkID="19001"&gt;prasugrel&lt;/ulink&gt; may not be the only oral antiplatelet agents available on the market at the time when SCH-530348 is submitted and evaluated for approval. Therefore, the established benefit of a third class of medications targeting platelets will need to be firmly demonstrated if other agents also exhibit improved outcomes compared with the current standard-of-care therapies. Head-to-head trials between SCH-530348 and one or more standard-of-care antiplatelet therapies may be required to solidify and justify the role of the PAR-1 receptor antagonist, particularly if optimization of P2Y12 receptor antagonism reduces the potential value of an additional antiplatelet medication. The pharmacoeconomic value of triple oral antiplatelet therapy will also be more difficult to establish compared with direct &lt;ulink linkType="Drug" linkID="2836"&gt;clopidogrel&lt;/ulink&gt; competitors.&lt;/para&gt;&lt;para&gt;Despite these potential hurdles for SCH-530348, a successful phase III clinical trial demonstrating additional efficacy over standard-of-care treatments and minimal safety risks would likely propel the PAR-1 antagonist into the clinical arena with an important role in the prevention of major adverse cardiovascular events. Therefore, the phase III trial results for this antiplatelet agent are highly anticipated.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1110015">Old API Wind-down Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-09-06T00:00:00.000Z</StatusDate><Source id="2014251" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1110015">Old API Wind-down Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-09-06T00:00:00.000Z</StatusDate><Source id="2014251" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1110015">Old API Wind-down Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-09-06T00:00:00.000Z</StatusDate><Source id="2014251" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-09-08T00:00:00.000Z</StatusDate><Source id="1736961" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-11-01T00:00:00.000Z</StatusDate><Source id="2089481" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-06-23T00:00:00.000Z</StatusDate><Source id="2135642" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-11-01T00:00:00.000Z</StatusDate><Source id="1990497" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-01-13T00:00:00.000Z</StatusDate><Source id="1161171" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19711">Schering-Plough Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19711">Schering-Plough Corp</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-09-06T00:00:00.000Z</StatusDate><Source id="2014251" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19711">Schering-Plough Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-09-06T00:00:00.000Z</StatusDate><Source id="1980644" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19711">Schering-Plough Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19711">Schering-Plough Corp</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-09-06T00:00:00.000Z</StatusDate><Source id="2014251" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19711">Schering-Plough Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-07-24T00:00:00.000Z</StatusDate><Source id="1456096" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-05-08T00:00:00.000Z</StatusDate><Source id="1554892" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-02-21T00:00:00.000Z</StatusDate><Source id="1536713" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1598606" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-05-13T00:00:00.000Z</StatusDate><Source id="1772444" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-09-08T00:00:00.000Z</StatusDate><Source id="1736961" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-11-04T00:00:00.000Z</StatusDate><Source id="1054580" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18077">Merck &amp; Co Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-01-19T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1076">Thrombosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-11-18T00:00:00.000Z</StatusDate><Source id="513822" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24009">Schering-Plough Research Institute</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1076">Thrombosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-08-04T00:00:00.000Z</StatusDate><Source id="335120" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-09-30T00:00:00.000Z</StatusDate><Source id="842624" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-09-30T00:00:00.000Z</StatusDate><Source id="842624" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-09-30T00:00:00.000Z</StatusDate><Source id="842624" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-12-19T00:00:00.000Z</StatusDate><Source id="785446" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-12-19T00:00:00.000Z</StatusDate><Source id="905535" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3258">Acute coronary syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-08-31T00:00:00.000Z</StatusDate><Source id="1017544" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19711">Schering-Plough Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-12-13T00:00:00.000Z</StatusDate><Source id="1105780" type="TRIALREG"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="18077">Merck &amp; Co Inc</OwnerCompany><Country id="US">US</Country><Indication id="3258">Acute coronary syndrome</Indication><AwardedIndication>Treatment of Ischemic heart disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-04-19T00:00:00.000Z</MileStoneDate><Source id="662596" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-02715"><Name>Protease-activated receptor-1</Name><SwissprotNumbers><Swissprot>P25116</Swissprot><Swissprot>P26824</Swissprot><Swissprot>P30558</Swissprot><Swissprot>P47749</Swissprot><Swissprot>P56488</Swissprot><Swissprot>Q00991</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>2 references added [&lt;ulink url="utility.reference?i_reference_id=2117385" linkType="reference" linkID="2117385"&gt;2117385&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2091595" linkType="reference" linkID="2091595"&gt;2091595&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1038240">National Centre in HIV Epidemiology and Clinical Research</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1110015">Old API Wind-down Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18077">Merck &amp; Co Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]3[C@H]([C@H]2/C=C/c4ccc(cn4)c5cccc(c5)F)[C@H](OC3=O)C</Smiles><Smiles>CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]3[C@H]([C@H]2/C=C/c4ccc(cn4)c5cccc(c5)F)[C@H](OC3=O)C.OS(=O)(=O)O</Smiles><Smiles>Cc1ccc(cc1)Cn2c3ccccc3n(c2=N)CC(=O)c4cc(c(c(c4)C(C)(C)C)O)C(C)(C)C</Smiles></StructureSmiles><Deals><Deal id="159354" title="Kirby Institute and Merck to conduct research on vorapaxar against HIV      "></Deal><Deal id="162199" title="Aralez acquires Merck's Zontivity in US and Canada                  "></Deal></Deals><PatentFamilies><PatentFamily id="108481" number="WO-2007075808" title="Methods for preventing and/or treating a cell proliferative disorder"></PatentFamily><PatentFamily id="1145890" number="WO-2008079260" title="Disintegration promoters in solid dose wet granulation formulations"></PatentFamily><PatentFamily id="1177599" number="WO-2006076452" title="An exo-selective synthesis of himbacine analogs"></PatentFamily><PatentFamily id="1181870" number="WO-2009124103" title="Combination therapies comprising PARL antagonists with PAR-4 antagonists"></PatentFamily><PatentFamily id="1291273" number="WO-2006076565" title="Preparation of chiral propargylic alcohol and ester intermediates of himbacine analogs"></PatentFamily><PatentFamily id="141364" number="WO-2006076415" title="Exo- and diastereo-selective syntheses of himbacine analogs"></PatentFamily><PatentFamily id="1488916" number="WO-03089428" title="Tricyclic thrombin receptor antagonists."></PatentFamily><PatentFamily id="1515429" number="WO-2008005344" title="Synthesis of 3-(5-nitrocyclohex-1-enyl) acrylic acid and esters thereof"></PatentFamily><PatentFamily id="1543217" number="WO-2007075964" title="Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery"></PatentFamily><PatentFamily id="1583829" number="WO-00196330" title="Thrombin receptor antagonists"></PatentFamily><PatentFamily id="1605612" number="WO-2010093629" title="PAR-1 antagonism in fed or antacid-dosed patients"></PatentFamily><PatentFamily id="1608850" number="WO-2008016378" title="Methods to treat and/or prevent radiation- and/or chemical-induced toxicity in non-malignant tissue"></PatentFamily><PatentFamily id="1807492" number="WO-2005030712" title="Thrombin receptor anatgonists"></PatentFamily><PatentFamily id="1880149" number="WO-2005046688" title="Methods of use of thrombin receptor antagonists"></PatentFamily><PatentFamily id="208348" number="US-20110065676" title="Combination therapies comprising PAR1 antagonists with NAR agonists"></PatentFamily><PatentFamily id="221448" number="WO-2008039406" title="Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist"></PatentFamily><PatentFamily id="2640919" number="WO-2013177473" title="Compositions and methods for assaying platelet reactivity and treatment selection"></PatentFamily><PatentFamily id="2961855" number="WO-2015090705" title="Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions"></PatentFamily><PatentFamily id="3134170" number="CN-105310991" title="&lt;para&gt;Vorapaxar tablet and preparation method thereof&lt;/para&gt;"></PatentFamily><PatentFamily id="3141451" number="CN-105348241" title="Synthesis method of vorapaxar sulfate intermediate"></PatentFamily><PatentFamily id="3208524" number="WO-2016095684" title="Himbacine analogue and method for preparing intermediate thereof"></PatentFamily><PatentFamily id="3227523" number="WO-2008005353" title="Immediate-release tablet formulations of a thrombin receptor antagonist"></PatentFamily><PatentFamily id="329358" number="WO-2006076564" title="Synthesis of himbacine analogs"></PatentFamily><PatentFamily id="339657" number="WO-2009055416" title="High purity synthetic process for the preparation of dodecahydro-naphtho-furanyl-carbamic acid ester intermediates"></PatentFamily><PatentFamily id="3521006" number="CN-106309396" title="A preparation method of vorapaxar preparation"></PatentFamily><PatentFamily id="3656199" number="CN-106699712" title="A vorapaxar intermediate and preparation method thereof"></PatentFamily><PatentFamily id="3668678" number="WO-2017086385" title="Ectopic ossification treatment drug having mechanism for blocking PAR1"></PatentFamily><PatentFamily id="367094" number="WO-2008005348" title="Synthesis of diethyl{ [5&quot; (3 -fluorophenyl) -pyridine-2-yl] methyl} phosphonate used in the synthesis of himbacine analogs"></PatentFamily><PatentFamily id="3674044" number="CN-106749201" title="Vorapaxar and intermediates thereof"></PatentFamily><PatentFamily id="3674107" number="CN-106749138" title="Method for preparing vorapaxar sulphate intermediate aldehyde"></PatentFamily><PatentFamily id="3710965" number="CN-106866450" title="Preparation method of sulphuric acid vorapaxar intermediate"></PatentFamily><PatentFamily id="3749505" number="WO-2017134199" title="A pharmaceutical composition of vorapaxar and metoprolol"></PatentFamily><PatentFamily id="3816205" number="IN-201621010411" title="Preparing vorapaxar involves cyclizing (e)-(nitro-cyclohexenyl)-acrylic acid (z)-(r)-carbamoyl-methyl-allyl ester to form mixture of exo-and endo isomers, epimerizing trans-(5,6)-ring-junction, precipitating and converting to vorapaxar"></PatentFamily><PatentFamily id="3933602" number="CN-107540564" title="A preparation method of vorapaxar intermediate"></PatentFamily><PatentFamily id="4043059" number="CN-107935883" title="A vorapaxar intermediate and preparation method thereof"></PatentFamily><PatentFamily id="4241726" number="CN-108658910" title="Preparation method of a vorapaxar intermediate 1 -&amp;amp;#945;"></PatentFamily><PatentFamily id="496357" number="WO-2008118320" title="Reduction of adverse events after percutaneous intervention by use of a thrombin receptor antagonist"></PatentFamily><PatentFamily id="508886" number="WO-2010144339" title="A thrombin receptor antagonist and clopidogrel fixed dose tablet"></PatentFamily><PatentFamily id="522210" number="WO-2010141525" title="Active metabolite of a thrombin receptor antagonist"></PatentFamily><PatentFamily id="567577" number="WO-2005070923" title="Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist"></PatentFamily><PatentFamily id="74477" number="US-20090297576" title="Local delivery of PAR-1 antagonists to treat vascular complications"></PatentFamily><PatentFamily id="848584" number="WO-2007117621" title="Use of combination preparations containing thrombin receptor antagonists for treating cardiovascular disorders"></PatentFamily><PatentFamily id="849652" number="WO-2008137673" title="Methods of measuring inhibition of platelet aggregation by thrombin receptor antagonists"></PatentFamily><PatentFamily id="894097" number="WO-2010057066" title="Pharmacokinetically-based dosing regimens of a thrombin receptor antagonist"></PatentFamily><PatentFamily id="996889" number="WO-2008005352" title="Solid dose formulations of a thrombin receptor antagonist"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>7</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>11</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>7</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="4">Delivery device</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>11</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>8</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanovel Ilac Sanayi Ve Tic-Aret Anonim Sirketi" id="1010709"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Accumetrics Inc" id="1012130"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The University of Arkansas System" id="1018113"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Yangtze River Pharmaceutical Group" id="1024536"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Brightgene Bio-Medical Technology Co Ltd" id="1025424"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hybio Pharmaceutical Co Ltd" id="1053968"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sino Biopharmaceutical Ltd" id="1073089"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Leadingpharm Medical Technology Co Ltd" id="1074211"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai SynCores Technologies Inc" id="1076463"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nanjing Huawe Medicine Technology Development Co Ltd" id="1076471"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Wanquan Dezhong Pharmaceutical Biotechnology Co Ltd" id="1085766"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai Bozhi Research Of New Drugs Technology Co Ltd" id="1085772"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Medtronic plc" id="1097361"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Beijing Sineva Technology Co Ltd" id="1127267"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"></CompanyLink><CountAsOwner>27</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>27</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pierre Fabre SA" id="19087"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Vermont" id="20694"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kumamoto University" id="21328"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alembic Ltd" id="29955"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cytori Therapeutics Inc" id="31598"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>